DRUG NAME: Cephalexin

INN: Cefalexin
Commonly used name in India: Cephalexin (the spelling “Cephalexin” is universally used on Indian product labels, prescriptions, and formularies — this monograph uses “Cephalexin” as the primary name, consistent with Indian practice)
USAN: Cephalexin

ℹ️ Salt form: Cephalexin is used clinically as the free base (anhydrous) or as cephalexin monohydrate. Doses are expressed in terms of cephalexin base activity. Both forms are bioequivalent — the monohydrate form is the more common manufacturing form in India. There is no clinically significant difference between the two, and prescribers need not specify the salt form. Capsule and tablet strengths (250 mg, 500 mg) refer to cephalexin base equivalent regardless of the salt used.

ℹ️ Relationship to other first-generation cephalosporins:

Drug	Route	Key Distinguishing Feature	Availability in India
Cephalexin	Oral	The most widely used oral first-generation cephalosporin worldwide and in India. Can be taken with or without food — a major practical advantage over anti-staphylococcal penicillins (cloxacillin/flucloxacillin).	✔ Widely available; on NLEM India 2022
Cefazolin	IV, IM	The preferred parenteral first-generation cephalosporin. Gold standard for surgical prophylaxis. Longer half-life than cephalexin (1.8–2.5 h).	✔ Widely available; on NLEM India 2022
Cefadroxil	Oral	Longer half-life (~1.5 h) allows twice-daily dosing. Comparable spectrum to cephalexin. Less widely used in India than cephalexin.	✔ Available
Cephradine	Oral, IV, IM	Very similar to cephalexin. Largely superseded by cephalexin in Indian practice.	Limited availability

💡 Why cephalexin matters in Indian clinical practice:
Cephalexin occupies a unique and important niche as an oral anti-staphylococcal and streptococcal agent that can be taken with food and dosed three times daily (TDS / q8h). This is a major practical advantage over cloxacillin and flucloxacillin, which must be taken on an empty stomach q6h (four times daily). While pharmacologically, cloxacillin/flucloxacillin are considered “first-line” for MSSA by many infectious disease guidelines, cephalexin is the preferred oral step-down agent in many real-world Indian clinical scenarios where:

Patient adherence to q6h empty-stomach dosing is unreliable
Outpatient/PHC settings where simpler regimens improve completion rates
Mild-to-moderate MSSA skin and soft tissue infections where food-independent absorption is advantageous
Oral step-down from IV cefazolin (pharmacological class consistency — both first-generation cephalosporins)

⚠️ Spectrum limitation: Cephalexin has NO activity against MRSA, Enterococcus, Pseudomonas, Acinetobacter, or anaerobes. It is NOT a broad-spectrum antibiotic. Its value is as a targeted Gram-positive agent with moderate Gram-negative coverage.

Therapeutic Class:

Antibiotic (Antibacterial)

Subclass:

First-generation cephalosporin (oral)

ℹ️ First-generation cephalosporins are characterised by excellent Gram-positive coverage (MSSA, streptococci) and limited but clinically useful Gram-negative coverage (E. coli, Klebsiella pneumoniae, Proteus mirabilis — community-acquired, non-ESBL strains). Activity decreases against Gram-negatives with each successive cephalosporin generation, while Gram-negative activity generally increases.

Schedule (India):

Schedule H

All formulations of cephalexin (capsules, tablets, dry syrup/oral suspension, drops) are classified under Schedule H. A valid prescription from a registered medical practitioner is required for dispensing.

No formulation of cephalexin has OTC (non-scheduled) status in India.

Route(s)

Oral (capsules, tablets, dry syrup/oral suspension, paediatric drops)

ℹ️ Cephalexin is an oral-only drug. There is no parenteral (IV/IM) formulation of cephalexin. The parenteral equivalent within the same generation is cefazolin (IV/IM). When transitioning from IV to oral therapy, cefazolin → cephalexin is a common and pharmacologically rational IV-to-oral switch (same generation, similar spectrum, both first-generation cephalosporins).

Biosimilar Status:

Not a biologic — biosimilar classification not applicable.

Cephalexin is a small-molecule, semi-synthetic antibiotic (a first-generation cephalosporin derived from 7-aminocephalosporanic acid, 7-ACA). It is manufactured as a conventional generic pharmaceutical product. Multiple generic manufacturers produce cephalexin in India.

Formulations Available in India

Single-ingredient formulations:

Dosage Form	Strengths Available	Notes
Capsules (cephalexin monohydrate or anhydrous)	250 mg, 500 mg	Most commonly prescribed form for adults and older children who can swallow capsules.
Tablets (film-coated or dispersible)	250 mg, 500 mg, 1 g (1000 mg — limited availability)	Some manufacturers produce 1 g tablets for high-dose adult therapy (e.g., osteomyelitis oral step-down). Dispersible tablets available from select manufacturers.
Dry syrup / Oral suspension (powder for reconstitution)	125 mg/5 mL, 250 mg/5 mL	Widely available. Primary formulation for paediatric use. Reconstitute with water before use.
Paediatric drops	125 mg/1.25 mL (i.e., 100 mg/mL) — select manufacturers	For infants and very young children where smaller volumes are needed. Limited availability — not all manufacturers produce this strength.

ℹ️ Capsule vs Tablet: Both are bioequivalent. Capsules are the traditional dosage form and remain the most widely prescribed. Tablets are available from some manufacturers and are preferred by patients who have difficulty swallowing capsules. Dispersible tablets can be dissolved in water — useful for elderly patients with swallowing difficulties or for enteral tube administration.

Fixed-Dose Combinations (FDCs) available in India:

ℹ️ Cephalexin has relatively few commonly used FDCs compared to some other antibiotics. The following are CDSCO-approved and in clinical use:

FDC Partner	Strengths Available	Route	Notes
Cephalexin + Probenecid	Capsules: Cephalexin 250 mg + Probenecid 250 mg	Oral	Available from limited manufacturers. Probenecid blocks renal tubular secretion of cephalexin → increased serum levels and prolonged half-life. Historically used to boost cephalosporin levels; rarely prescribed in current Indian practice.

ℹ️ Unlike the ampicillin-cloxacillin or amoxicillin-clavulanate combinations, cephalexin is not commonly combined with other antibiotics in a single FDC formulation. Combination antibiotic therapy involving cephalexin (e.g., cephalexin + metronidazole for mixed aerobic-anaerobic infections) is prescribed as separate pills, not as an FDC.

⛔ Banned FDCs containing cephalexin:
No FDC containing cephalexin as a component has been specifically banned by CDSCO as of the latest gazette notifications reviewed (2024). Prescribers should verify the current CDSCO banned drug list periodically.

PHARMACOKINETICS

Parameter	Value
Bioavailability (oral)	~90–95% — excellent oral bioavailability. One of the best-absorbed oral cephalosporins. Absorption is nearly complete from the GI tract. This high and reliable bioavailability is a key clinical advantage — oral cephalexin achieves serum levels that are a high proportion of what IV cefazolin achieves.
Tmax	~1 hour (fasting); ~1.5–2 hours (with food). Food delays absorption slightly but does NOT significantly reduce total absorption (AUC).
Protein binding	~10–15% — very low protein binding. This means that nearly 85–90% of circulating cephalexin is free (unbound) and microbiologically active. This is clinically advantageous — the free drug concentration approximates the total drug concentration, and hypoalbuminaemia (ICU, cirrhosis, nephrotic syndrome) does NOT meaningfully alter free drug levels.
Volume of distribution (Vd)	~0.25–0.35 L/kg (~18–25 L in a 70 kg adult). Distributes well into extracellular fluid, tissues, and body fluids including: skin and soft tissue blister fluid (good — relevant for SSTI), bone (moderate — adequate for osteomyelitis at high doses), kidney and urinary tract (excellent — high urinary concentrations), middle ear fluid, tonsils, respiratory secretions (moderate), breast milk (low levels). Poor CSF penetration even with inflamed meninges — NOT suitable for CNS infections.
Metabolism	Not significantly metabolised. Cephalexin is excreted unchanged — no hepatic metabolism, no CYP450 involvement, no active metabolites. This is a major pharmacological advantage: (1) No drug interactions via CYP pathways, (2) No hepatic dose adjustment required, (3) Drug levels are predictable. Cephalexin is NOT a substrate, inhibitor, or inducer of any CYP450 enzymes. It is NOT a significant substrate or inhibitor of P-glycoprotein, OATP1B1/1B3, BCRP, or MATE1/2 at therapeutic concentrations. It is a substrate of OAT1/OAT3 (renal organic anion transporters) and PEPT1 (intestinal peptide transporter — responsible for active intestinal absorption).
Half-life (t½)	~0.6–1.2 hours (mean ~1 hour) in adults with normal renal function. This short half-life necessitates dosing every 6–8 hours (q6h for serious infections; q8h for mild-moderate infections). Prolonged in renal impairment: up to 5–6 hours at CrCl <10 mL/min; up to 20–40 hours in anuria. Neonates: 3–5 hours (immature renal function).
Excretion	Primarily renal: ~80–95% excreted unchanged in urine via both glomerular filtration and active tubular secretion (via OAT1/OAT3 transporters). Achieves very high urinary concentrations (~500–1000 mcg/mL within the first 6 hours after a 500 mg dose) — highly relevant for UTI treatment. Minor faecal excretion (<5%).
Dialysability	Moderately dialysable by haemodialysis — approximately 30–40% removed in a standard 4-hour HD session (low protein binding + moderate Vd). Supplemental dose required post-HD (see Renal Adjustment, Part 4). Peritoneal dialysis removes cephalexin less efficiently (~10–15%).
Food effect	Not clinically significant. Food slightly delays Tmax (from ~1 h to ~1.5–2 h) and marginally reduces Cmax, but the total absorption (AUC) is NOT significantly reduced. ✔ Cephalexin CAN be taken with or without food. This is a major practical advantage over cloxacillin/flucloxacillin (which must be taken on empty stomach) and is one of the primary reasons cephalexin is preferred for oral step-down and outpatient therapy in Indian practice. Taking with food may reduce GI side effects (nausea, stomach upset).
Onset of action	Clinical onset: ~1–2 hours after oral dose (time to achieve therapeutic serum and tissue levels). Clinical improvement in infections: typically 48–72 hours.
Duration of action	~6–8 hours per dose (based on time serum levels remain above MIC for susceptible organisms). Short duration necessitates dosing every 6–8 hours. For organisms with higher MICs or in situations requiring more aggressive therapy, q6h dosing is preferred. For mild infections with susceptible organisms, q8h (TDS) is adequate and improves adherence.

Non-linear PK:
No clinically significant non-linear pharmacokinetics at therapeutic doses. Absorption may plateau at very high single doses (>4 g at once — not used clinically) due to saturation of intestinal PEPT1 transporter-mediated absorption. At standard therapeutic doses (250 mg–1 g per dose), PK is essentially linear.

Prodrug status: Cephalexin is NOT a prodrug. The parent compound is the active antibacterial moiety.

Population PK Notes:

Population	PK Differences
Obesity	Cephalexin’s moderate Vd (~0.25–0.35 L/kg) suggests that morbidly obese patients may have somewhat lower peak concentrations if dosed on total body weight. However, standard fixed dosing (500 mg q8h or q6h) is generally adequate for most infections in obese patients with normal renal function. For serious infections in morbidly obese patients (e.g., SSTI with extensive tissue involvement), use the higher end of the dose range (1 g q6h). Specific PK studies in obesity are limited.
Pregnancy	Increased Vd (plasma volume expansion ~40–50%) and increased GFR (~50% increase) during pregnancy → lower cephalexin serum levels at standard doses. However, since cephalexin achieves very high urinary concentrations, its efficacy for UTI (the most common indication in pregnancy) is generally preserved. For non-UTI infections in pregnancy, use the higher end of the dose range. PK modelling suggests standard dosing is adequate for most indications.
Critical illness / ICU	Cephalexin is rarely the drug of choice in the ICU (parenteral cefazolin or broader-spectrum agents are preferred). If used orally in a recovering ICU patient (step-down), altered Vd and renal function should be considered. ARC may reduce levels — though cephalexin is rarely used in the ARC population (parenteral agents are preferred in this setting).
Paediatric	Higher per-kg clearance in children compared to adults. Neonates have prolonged half-life (3–5 hours) due to immature renal function. Weight-based dosing (mg/kg) accounts for the higher per-kg requirements in children. Oral absorption is generally reliable in children >1 month of age.
Elderly (≥60 years)	Clearance is reduced proportionally to age-related decline in renal function. Half-life may be prolonged to 1.5–3 hours or longer depending on GFR. Always estimate renal function before prescribing in elderly. Dose adjustment is based on CrCl/eGFR rather than age per se. No specific PK changes beyond renal considerations.

Spectrum of Activity — Quick Reference:

ℹ️ This spectrum summary is essential context for all indication and dosing sections in Part 2.

Category	Typical Activity
Gram-positive (aerobic)	✔ Staphylococcus aureus (MSSA only — NOT MRSA): Good activity. Cephalexin is effective against penicillinase-producing MSSA (beta-lactamases of staphylococci generally do NOT hydrolyse first-generation cephalosporins). ✔ Streptococci: Excellent activity against S. pyogenes (Group A Streptococcus — GAS), Group B Streptococcus (GBS), S. pneumoniae (penicillin-susceptible). ✔ Coagulase-negative staphylococci (methicillin-sensitive only).
Gram-negative (aerobic)	✔ Community-acquired, non-ESBL E. coli: Good activity. ✔ Klebsiella pneumoniae: Moderate (community-acquired, non-ESBL strains only). ✔ Proteus mirabilis: Good. ⚠️ Activity against Gram-negatives is limited to community-acquired, non-resistant strains. Hospital-acquired and ESBL-producing Enterobacterales are resistant.
NO activity against	⛔ MRSA (methicillin-resistant S. aureus); ⛔ Enterococcus spp. (intrinsically resistant to all cephalosporins — a fundamental pharmacological principle); ⛔ Pseudomonas aeruginosa; ⛔ Acinetobacter baumannii; ⛔ ESBL-producing Enterobacterales; ⛔ Anaerobes (cephalexin has negligible anaerobic activity — unlike cefoxitin or piperacillin-tazobactam); ⛔ Stenotrophomonas maltophilia; ⛔ Atypical pathogens (Mycoplasma, Chlamydia, Legionella); ⛔ Listeria monocytogenes (intrinsically resistant); ⛔ Haemophilus influenzae — variable, borderline activity (second- and third-gen cephalosporins preferred)

⚠️ Critical Indian context — resistance data:
Indian community-acquired E. coli and K. pneumoniae show increasing resistance to first-generation cephalosporins due to ESBL production and AmpC beta-lactamases. ICMR AMR surveillance data (2022–2023) suggests:

Community-acquired E. coli — cephalexin susceptibility: approximately 50–65% (varies by region)
Community-acquired K. pneumoniae — cephalexin susceptibility: approximately 40–55% (varies)
These rates are LOWER than in many Western countries due to higher background resistance in India

💡 Implication: Cephalexin remains a useful agent for uncomplicated community-acquired UTIs in India, but empiric use should be guided by local antibiogram data where available. For Gram-positive infections (SSTI — MSSA, streptococcal), resistance is not a significant concern (MSSA and GAS remain highly susceptible to cephalexin).

Key PK Comparison: Cephalexin vs Cloxacillin vs Flucloxacillin (for Anti-Staphylococcal Oral Therapy)

Parameter	Cephalexin	Cloxacillin	Flucloxacillin
Oral bioavailability	~90–95%	~37–50%	~50–70%
Food effect on absorption	Negligible	~50% reduction	~25–35% reduction
Empty-stomach requirement	✔ NOT required	⚠️ REQUIRED (1 h before or 2 h after meals)	⚠️ REQUIRED (30–60 min before meals)
Dosing frequency	q8h (TDS) or q6h (QDS)	q6h (QDS) mandatory	q6h (QDS) mandatory
Half-life	~0.6–1.2 h	~0.5–1.1 h	~0.75–1.5 h
Protein binding	~10–15% (very low)	~94–96% (very high)	~95–96% (very high)
Free (unbound) fraction	~85–90%	~4–6%	~4–5%
Hepatotoxicity risk	Very low	Low–moderate	⚠️ Higher (HLA-B*57:01 associated)
NLEM India status	✔ On NLEM 2022	✔ On NLEM 2022	✘ Not on NLEM
Availability in India	✔ Widely available	✔ Widely available	Limited
Anti-MSSA potency (MIC)	Good (MIC₉₀ ~4–8 mg/L)	Excellent (MIC₉₀ ~0.5–1 mg/L)	Excellent (MIC₉₀ ~0.5–1 mg/L)

💡 Clinical interpretation of this comparison:

Cloxacillin/flucloxacillin have lower MICs against MSSA — they are pharmacologically more potent on a per-mg basis. For serious, deep-seated MSSA infections (bacteraemia, endocarditis, osteomyelitis), anti-staphylococcal penicillins are preferred.
Cephalexin compensates for its higher MICs with its dramatically higher free drug fraction (~85–90% free vs ~4–6% free for cloxacillin). The free drug concentration driving bactericidal activity is therefore more comparable than the total drug concentrations suggest.
Cephalexin’s food-independent absorption and TDS dosing give it a major practical adherence advantage — and adherence is arguably the single most important determinant of oral antibiotic efficacy in outpatient practice.
For mild-to-moderate MSSA SSTI, cephalexin is widely considered clinically equivalent to cloxacillin/flucloxacillin in outcome studies — the theoretical potency advantage of the penicillins is offset by better adherence with cephalexin.
For oral step-down in serious infections (osteomyelitis, bacteraemia follow-on), expert opinion varies:
- Some ID specialists prefer flucloxacillin 1 g q6h (OVIVA trial precedent)
- Others use cephalexin 1 g q6h or q8h (simpler regimen, better adherence)
- API Textbook and AIIMS protocols variably reference both approaches

ADULT INDICATIONS + DOSING

⛔ CRITICAL PRESCRIBING PRINCIPLES — READ BEFORE ALL INDICATIONS:

1. Cephalexin is a NARROW-SPECTRUM, Gram-positive-focused oral antibiotic.
It is NOT a broad-spectrum agent. Its primary value is as an oral anti-staphylococcal (MSSA) and anti-streptococcal agent with moderate activity against community-acquired, non-ESBL Gram-negatives. Prescribing cephalexin for infections likely caused by MRSA, Enterococcus, Pseudomonas, anaerobes, or ESBL-producing organisms is inappropriate and constitutes an antibiotic stewardship failure.

2. Culture-guided therapy is always preferred over empiric therapy when feasible.
While cephalexin is commonly used empirically for outpatient SSTI and UTI, obtaining cultures (wound swab, urine culture) before or early during therapy improves outcomes and guides de-escalation or escalation.

3. Cephalexin is an ORAL-ONLY drug.
There is no IV or IM formulation. For patients who require parenteral therapy initially, the pharmacologically rational parenteral equivalent is cefazolin (IV/IM) — same generation, similar spectrum. The IV cefazolin → oral cephalexin switch is one of the most established and evidence-supported IV-to-oral transitions in infectious disease practice.

4. Enterococcal coverage gap — a fundamental pharmacological limitation of ALL cephalosporins.
⛔ No cephalosporin — first through fifth generation — has reliable activity against Enterococcus species. This is clinically critical for:

UTI (Enterococcus is a common uropathogen, especially in catheterised/complicated UTI)
Intra-abdominal infections (enterococcal component often present)
Endocarditis (Enterococcus is a major cause)
If Enterococcus is suspected or isolated, cephalexin is inappropriate — use ampicillin or amoxicillin.

5. No anaerobic coverage.
Cephalexin should NOT be used as monotherapy for infections with a significant anaerobic component (bite wounds, dental abscesses with deep-space spread, intra-abdominal infections, aspiration pneumonia). For mixed aerobic-anaerobic infections, either add metronidazole or switch to amoxicillin-clavulanate.

GENERAL DOSING FRAMEWORK — Applicable Across Indications:

ℹ️ Since cephalexin is oral-only, all dosing is by mouth. The following general framework applies unless modified by specific indications:

Dosing Parameter	Standard Adult Dosing
Mild-to-moderate infections	250–500 mg q8h (TDS) or q6h (QDS)
Moderate-to-severe infections	500 mg–1 g q6–8h
Serious infections (e.g., osteomyelitis oral step-down)	1 g q6h (4 g/day — high-dose strategy)
Maximum dose	Max 1 g per dose; Max 4 g per day
Take with or without food	✔ Either acceptable. Taking with food may reduce GI upset.

Primary Indications (Approved / Standard in India)

PRIMARY INDICATION 1: Skin and Soft Tissue Infections (SSTI) — MSSA / Streptococcal

Includes: Cellulitis (non-purulent and purulent — when MSSA suspected/confirmed), impetigo (non-bullous and bullous), wound infections, furunculosis, carbuncle, folliculitis, erysipelas, infected eczema, post-surgical wound infection (MSSA/streptococcal), infected burns (superficial, MSSA/streptococcal), pyoderma, paronychia (acute bacterial), secondary skin infections.

ℹ️ SSTI is the most important and most common indication for cephalexin in Indian outpatient practice. It is the mainstay oral antibiotic for mild-to-moderate SSTI caused by MSSA and beta-haemolytic streptococci.

Dosing Table — SSTI:

Severity	Dose	Frequency	Maximum	Duration	Clinical Notes
Mild SSTI (localised impetigo, small folliculitis, minor wound infection)	250 mg	q8h (TDS)	Max 250 mg per dose; Max 750 mg/day	5–7 days	For limited impetigo, topical mupirocin or fusidic acid alone may suffice — cephalexin reserved for extensive or topical-failure cases.
Moderate SSTI (cellulitis without systemic signs, larger abscess post-drainage, extensive impetigo, furunculosis)	500 mg	q8h (TDS) or q6h (QDS)	Max 500 mg per dose; Max 2 g/day	5–7 days (cellulitis may extend to 10 days if slow response)	Most common prescription. Take with or without food.
Moderate-to-severe SSTI (cellulitis with spreading erythema, large carbuncle, deep wound infection, extensive pyoderma)	500 mg–1 g	q6h (QDS)	Max 1 g per dose; Max 4 g/day	7–10 days	Higher dose range. q6h dosing provides better fT>MIC for organisms with higher MICs. Consider IV cefazolin if systemic signs present (fever >38.5°C, tachycardia, hypotension).

Duration of Therapy — SSTI:

Condition	Recommended Duration
Impetigo	5–7 days
Simple cellulitis	5 days (recent evidence supports short courses if responding — DANCE trial, 2017)
Moderate cellulitis	5–7 days (extend to 10 if slow response)
Abscess (post I&D) — antibiotics adjunctive	5–7 days
Furunculosis / carbuncle	7–10 days
Wound infection (post-surgical)	7–14 days depending on depth

ℹ️ Short-course evidence for cellulitis: The DANCE trial (Dan et al., Clin Infect Dis 2017) demonstrated that 5 days of antibiotic therapy is non-inferior to 10 days for uncomplicated cellulitis when clinical improvement is evident at day 5. This shorter-course approach is increasingly adopted in Indian dermatology and ID practice.

ℹ️ Purulent vs Non-purulent SSTI distinction:

Non-purulent cellulitis (no abscess, no pus): Most commonly caused by beta-haemolytic streptococci (Group A — S. pyogenes). Cephalexin provides excellent coverage.
Purulent SSTI (abscess, furuncle, carbuncle, purulent drainage): Most commonly caused by S. aureus (MSSA or MRSA). If MSSA → cephalexin is appropriate. If MRSA → cephalexin is ineffective.
⚠️ In India, distinguish MRSA from MSSA clinically and microbiologically: If the patient has risk factors for CA-MRSA (recurrent boils, household contacts with MRSA, prior MRSA isolation, failure of beta-lactam therapy), obtain wound culture before starting cephalexin. If MRSA is confirmed → switch to cotrimoxazole (TMP-SMX) 960 mg BD, doxycycline 100 mg BD, or clindamycin 300 mg q8h (for community MRSA SSTI).

Mandatory Clinical Notes Checklist — SSTI:

When to prefer cephalexin over alternatives: Cephalexin is preferred over cloxacillin for outpatient oral MSSA/streptococcal SSTI when: (a) Patient adherence to q6h empty-stomach dosing is unlikely (most outpatients), (b) TDS dosing improves compliance, © Food-independent absorption is advantageous. Preferred over amoxicillin-clavulanate when: (a) Infection is purely staphylococcal/streptococcal without anaerobic or resistant Gram-negative concern, (b) Narrower spectrum is preferred (stewardship advantage), © Lower cost is important. IDSA SSTI Guidelines (2014) list cephalexin as first-line oral agent for non-purulent cellulitis. API Textbook references cephalexin as an acceptable first-generation cephalosporin for MSSA SSTI.
When NOT to use:
- ⛔ Suspected or confirmed MRSA → use TMP-SMX, doxycycline, or clindamycin
- ⛔ Bite wounds (animal or human) → anaerobic component → use amoxicillin-clavulanate
- ⛔ Diabetic foot infection (polymicrobial) → cephalexin monotherapy is insufficient (Gram-negatives + anaerobes need coverage) → use amoxicillin-clavulanate, or piperacillin-tazobactam for moderate-severe
- ⛔ Necrotising fasciitis → requires IV broad-spectrum + surgical emergency
- ⛔ Perianal / perineal SSTI → anaerobic component likely → add metronidazole or use amoxicillin-clavulanate
- ⛔ Patient with history of anaphylaxis to penicillins — see cross-reactivity guidance (Part 4)
NLEM India status: ✔ Cephalexin is included in NLEM India 2022.
Typical time to clinical response: 48–72 hours. Cellulitis erythema margins should stop advancing; warmth and tenderness should begin improving. Mark the erythema border with a pen to objectively track progression/regression.
Criteria for considering treatment failure and switching:
- No improvement at 72 hours → (a) reassess diagnosis (is it truly infectious? Consider DVT, contact dermatitis, stasis dermatitis in leg cellulitis), (b) obtain wound culture if not done, © consider MRSA → switch to TMP-SMX/doxycycline/clindamycin, (d) consider deeper infection (abscess, necrotising) → imaging + surgical consultation
- Worsening despite 48 hours → urgent reassessment, consider IV antibiotics (cefazolin or broader if polymicrobial concern)
Mandatory baseline investigations before starting:
- RECOMMENDED: Wound swab culture and sensitivity (before starting, when feasible — especially if purulent, recurrent, or treatment failure). In PHC settings where culture is unavailable, empiric therapy is acceptable for first episodes of uncomplicated SSTI.
- OPTIONAL: CBC, blood glucose (screen for diabetes in recurrent SSTI), renal function (if prolonged course planned)
Specialist initiation: Not required. Primary care prescribing is appropriate for mild-to-moderate SSTI. Complicated, non-responding, or necrotising SSTI should be referred for surgical and/or ID opinion.
Relevant Indian guideline source: API Textbook of Medicine (current edition), Chapter on Skin and Soft Tissue Infections. ICMR Antimicrobial Treatment Guidelines (2022). AIIMS Antibiotic Policy. International: IDSA SSTI Guidelines (Deron et al., 2014) — widely followed in Indian practice.
Key disease-specific safety warning: ⚠️ In recurrent SSTI (≥3 episodes in 12 months), consider: (a) nasal MRSA/MSSA decolonisation (mupirocin nasal ointment BD × 5 days + chlorhexidine body wash × 5 days), (b) screen and treat household contacts, © screen for diabetes (very common in Indian patients with recurrent SSTI), (d) assess for immunodeficiency if infections are unusually severe or frequent.
Common clinical scenarios where dose adjustment is needed:
- Renal impairment (eGFR <30): Extend dosing interval — see Part 4
- Obese patients: Use 500 mg–1 g q6–8h (higher end of range)
- Elderly: Adjust for renal function; standard dose if eGFR >60

PRIMARY INDICATION 2: Uncomplicated Urinary Tract Infections (Acute Cystitis)

ℹ️ Cephalexin is a commonly used second-line agent for uncomplicated acute cystitis (acute lower UTI) in women. It is NOT the preferred first-line agent (nitrofurantoin, fosfomycin, and TMP-SMX are preferred when susceptible) — but it is widely used in Indian practice due to availability, tolerability, and familiarity.

Dosing — Acute Uncomplicated Cystitis:

Dose	Frequency	Maximum	Duration	Clinical Notes
250–500 mg	q6h (QDS) or q8h (TDS)	Max 500 mg per dose; Max 2 g/day	3–7 days (5 days typical for cephalexin; 3-day courses less well-validated for cephalexin compared to TMP-SMX or fluoroquinolones)	q8h dosing (250 mg TDS) acceptable for uncomplicated cystitis with susceptible organism. q6h dosing (500 mg QDS) for moderate/resistant cases.

ℹ️ Duration note: Unlike TMP-SMX (3 days) or nitrofurantoin (5 days) or fosfomycin (single dose), the optimal duration for cephalexin in acute cystitis is less precisely defined by RCTs. Most Indian practice uses 5–7 days. The IDSA/ESCMID uncomplicated UTI guidelines (2011, 2024 update) list cephalexin as a “second-line alternative” with a recommended duration of 5 days.

Dosing — Acute Pyelonephritis (Mild, Outpatient Management):

ℹ️ For mild acute pyelonephritis manageable in the outpatient setting (no vomiting, no sepsis signs, reliable patient for follow-up), cephalexin is NOT the preferred empiric agent — fluoroquinolones (ciprofloxacin, levofloxacin) or TMP-SMX (if susceptible) are preferred due to better renal tissue penetration. However, cephalexin may be used for directed therapy if the organism is susceptible and the patient cannot tolerate or has contraindications to fluoroquinolones/TMP-SMX.

Dose	Frequency	Maximum	Duration	Notes
500 mg	q6h (QDS)	Max 500 mg per dose; Max 2 g/day	10–14 days	Directed therapy only (culture-confirmed susceptible organism). NOT for empiric pyelonephritis. Ensure follow-up urine culture at end of therapy.

Mandatory Clinical Notes Checklist — UTI:

When to prefer cephalexin: Cephalexin is preferred over amoxicillin-clavulanate for uncomplicated cystitis when the organism is susceptible (cephalexin is narrower-spectrum — stewardship advantage). Preferred when nitrofurantoin is contraindicated (eGFR <30 — nitrofurantoin contraindicated) or when fosfomycin is unavailable/unaffordable. Preferred over fluoroquinolones for uncomplicated cystitis because fluoroquinolones should be reserved for more serious infections (stewardship — ICMR AMR guidelines). Commonly used in pregnancy-associated UTI as a second-line agent (see Pregnancy, Part 4).
When NOT to use:
- ⛔ Complicated UTI (structural abnormality, catheter-associated, recurrent, male UTI, urosepsis) → broader agents preferred (fluoroquinolone, piperacillin-tazobactam, carbapenem — depending on severity)
- ⛔ Suspected ESBL-producing organism (prior ESBL UTI, recent hospitalisation, recent broad-spectrum antibiotic use) → use nitrofurantoin (still effective against many ESBLs for cystitis) or fosfomycin or carbapenem (for pyelonephritis)
- ⛔ Enterococcal UTI → cephalexin has NO enterococcal activity → use amoxicillin or ampicillin
- ⛔ Pseudomonas UTI → no activity → use ciprofloxacin, piperacillin-tazobactam, or aminoglycoside
- ⛔ Empiric pyelonephritis (first-line) → fluoroquinolone or parenteral agent preferred
- ⚠️ In India, community E. coli susceptibility to cephalexin is ~50–65% (variable by region) → empiric cephalexin for UTI carries a ~35–50% risk of failure if the organism is resistant → always obtain urine culture
NLEM status: ✔ On NLEM.
Time to clinical response: Symptom improvement (frequency, dysuria) expected within 24–48 hours. If no improvement by 48–72 hours → suspect resistance → check urine culture results and switch accordingly.
Treatment failure criteria: Persistent symptoms at 72 hours; positive repeat urine culture after completing therapy; early recurrence (<2 weeks) → reassess: urine culture, renal imaging (US KUB), consider structural/anatomical cause, consider resistant organism.
Mandatory baseline investigations:
- RECOMMENDED: Urine culture and sensitivity (midstream clean-catch) BEFORE starting antibiotic — especially in India where resistance rates are high. Empiric therapy can be started while awaiting results (culture takes 24–48 hours).
- MANDATORY (in certain groups): Pregnant women, males, recurrent UTI, complicated UTI, treatment failure → urine culture is MANDATORY before (re)starting therapy.
- OPTIONAL: Dipstick urinalysis (nitrite + leukocyte esterase) — supportive but not definitive.
Specialist initiation: Not required for uncomplicated cystitis — primary care prescribing appropriate. Complicated UTI, pyelonephritis, or recurrent UTI → urology/nephrology/ID referral recommended.
Indian guideline source: API Textbook of Medicine; ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2022); AIIMS Antibiotic Policy; International: IDSA/ESCMID Uncomplicated UTI Guidelines (2011/2024 update — widely followed in India).
Key disease-specific safety warning: ⚠️ Indian antibiotic resistance context: Fluoroquinolone resistance in community E. coli in India is ~60–75% (very high). Cephalexin resistance is ~35–50%. Nitrofurantoin resistance remains relatively low (~10–20%). Fosfomycin resistance is also low (~5–15%). For empiric uncomplicated cystitis in India, nitrofurantoin remains the best first-line choice (ICMR recommendation) when the patient is not pregnant with eGFR <30. Cephalexin is acceptable but carries a higher empiric failure rate due to Indian resistance patterns.
Dose adjustment: Renal impairment → see Part 4 (very important for UTI patients who may already have renal compromise). No dose adjustment needed for hepatic impairment.

PRIMARY INDICATION 3: Acute Pharyngitis / Tonsillitis — Group A Streptococcus (GAS)

ℹ️ Cephalexin is an established alternative to penicillin V (phenoxymethylpenicillin) and amoxicillin for GAS pharyngitis. While penicillin V/amoxicillin remain the standard first-line (narrow-spectrum, cheap, highly effective, well-established for rheumatic fever prevention), cephalexin is an excellent option when penicillin is not tolerated or when first-generation cephalosporin use is preferred.

⚠️ Indian rheumatic heart disease (RHD) context: India has the highest burden of RHD globally. Adequate treatment of GAS pharyngitis is the primary prevention strategy for acute rheumatic fever (ARF) and RHD. Complete eradication of GAS from the pharynx (not just symptom resolution) is the therapeutic goal. This requires a full 10-day course of antibiotics — shortened courses carry a higher risk of treatment failure and persistent carriage.

Dosing — GAS Pharyngitis:

Dose	Frequency	Maximum	Duration	Clinical Notes
500 mg	q12h (BD) or q8h (TDS)	Max 500 mg per dose; Max 1.5 g/day	10 days (MUST complete full 10-day course — critical for rheumatic fever prevention)	BD dosing (500 mg q12h = 1 g/day) is supported by evidence (Pichichero et al.) and improves adherence. TDS dosing (500 mg q8h = 1.5 g/day) is an alternative. ⚠️ Do NOT shorten below 10 days.

ℹ️ Twice-daily cephalexin for GAS pharyngitis — evidence note: Several RCTs (Pichichero et al., 2000; Casey and Pichichero, 2004) have demonstrated that cephalexin 500 mg BD for 10 days achieves bacteriological eradication rates comparable to penicillin V QDS for 10 days. This BD regimen significantly improves adherence (two doses vs four) while maintaining efficacy for ARF prevention. This is particularly valuable in Indian practice where adherence to multi-dose regimens is a major challenge, especially in children and rural populations.

Mandatory Clinical Notes Checklist — GAS Pharyngitis:

When to prefer cephalexin: (a) Patient has non-anaphylactic penicillin allergy (cephalexin cross-reactivity ~1–2% — see Part 4). (b) Improved adherence desired — BD dosing is simpler than QDS penicillin V. © Treatment failure with penicillin (some evidence of higher bacteriological cure rates with cephalosporins vs penicillin — meta-analysis by Casey & Pichichero). (d) Recurrent GAS pharyngitis — some guidelines suggest cephalosporin course for recurrence after penicillin failure. ⚠️ However, amoxicillin (50 mg/kg/day in 2–3 divided doses × 10 days, or 750 mg–1 g once daily × 10 days in adults) remains the preferred first-line agent in Indian practice (ICMR, IAP).
When NOT to use:
- ⛔ History of anaphylaxis to penicillin → avoid cephalexin (cross-reactivity risk, though low) → use azithromycin 500 mg OD × 5 days (or clindamycin)
- ⛔ Suspected peritonsillar abscess or deep neck space infection → requires IV antibiotics + surgical drainage
- ⛔ Non-streptococcal pharyngitis (viral, most cases) → antibiotics NOT indicated; diagnose with Centor/McIsaac score ± rapid antigen detection test (RADT) ± throat culture
NLEM status: ✔ On NLEM.
Time to response: Symptom improvement (fever, throat pain) within 24–48 hours. If no improvement by 48–72 hours → reassess (peritonsillar abscess? Non-GAS aetiology? Poor adherence?).
Treatment failure criteria: Persistent symptoms at 72 hours; positive throat culture after completing therapy (persistent carriage); recurrence within 2–4 weeks of completing therapy.
Mandatory baseline investigations:
- RECOMMENDED: Clinical assessment using Modified Centor / McIsaac Score to estimate GAS probability. RADT (rapid antigen detection test) for GAS if available. Throat culture is the gold standard but takes 24–48 hours — not available at most PHC/CHC settings in India.
- In resource-limited settings: Treat based on Centor score ≥3 (clinical criteria) if RADT/culture unavailable. The risk of undertreating GAS pharyngitis in India (ARF/RHD prevention) generally outweighs the risk of unnecessary antibiotic exposure.
Specialist initiation: Not required — primary care prescribing appropriate. ENT referral for recurrent pharyngitis (≥7 episodes/year or ≥5/year for 2 consecutive years) or peritonsillar abscess.
Indian guideline source: API Textbook; IAP guidelines (paediatric pharyngitis — GAS treatment is predominantly a paediatric issue); ICMR AMR guidelines; ICRP (Indian Council of Rheumatic Prevention) — guidelines on ARF/RHD prevention.
Key disease-specific safety warning: ⚠️ Do NOT shorten the 10-day course. In India, where RHD burden is enormous, incomplete GAS eradication from the pharynx increases the risk of ARF. Even if symptoms resolve in 2–3 days, the full 10-day course is essential. Counsel patients/families explicitly: “You must take this medicine for the full 10 days, even if you feel completely better after 2–3 days.”
Dose adjustment: Renal impairment → adjust per Part 4. No hepatic adjustment needed.

PRIMARY INDICATION 4: Acute Otitis Media (AOM)

ℹ️ Amoxicillin is the undisputed first-line agent for AOM in India (and worldwide). Cephalexin is a second-line alternative — used when amoxicillin is not tolerated (non-anaphylactic allergy) or has failed.

⚠️ Important pharmacological note: Cephalexin has borderline activity against Haemophilus influenzae (a common AOM pathogen alongside S. pneumoniae and Moraxella catarrhalis). Second-generation cephalosporins (cefuroxime axetil) or amoxicillin-clavulanate provide better Haemophilus coverage and are preferred over cephalexin as second-line agents for AOM by most guidelines (AAP, IAP). Cephalexin is appropriate primarily when the likely pathogen is S. pneumoniae or GAS.

Dosing — AOM (Adults):

Dose	Frequency	Maximum	Duration	Clinical Notes
500 mg	q8h (TDS)	Max 500 mg per dose; Max 1.5 g/day	5–7 days (mild-moderate AOM in adults); 10 days (severe or recurrent)	Second-line — use only if amoxicillin not tolerated. Amoxicillin-clavulanate or cefuroxime axetil are preferred second-line agents with better H. influenzae coverage.

Mandatory Clinical Notes Checklist — AOM:

When to prefer cephalexin: Only when amoxicillin is not tolerated (non-anaphylactic penicillin allergy or GI intolerance) AND cefuroxime axetil and amoxicillin-clavulanate are also unavailable or not tolerated. Cephalexin is pharmacologically inferior to these agents for AOM due to borderline Haemophilus coverage.
When NOT to use: ⛔ Suspected mastoiditis or intracranial complication → IV antibiotics; ⛔ Chronic suppurative otitis media (CSOM) → different pathogens, different management; ⛔ History of penicillin anaphylaxis → risk of cross-reactivity with cephalosporins.
NLEM status: ✔ On NLEM.
Time to response: 48–72 hours.
Treatment failure: Persistent symptoms at 72 hours → reassess → switch to amoxicillin-clavulanate or cefuroxime axetil.
Mandatory baseline: Otoscopic examination (MANDATORY). Tympanocentesis reserved for complicated/recurrent cases.
Specialist initiation: Not required for uncomplicated AOM. ENT referral for complications or recurrent AOM.
Indian guideline source: IAP Guidelines (paediatric — AOM is primarily paediatric; adult AOM is less common); API Textbook; International: AAP AOM Guidelines (2013).
Key safety warning: ⚠️ Do not confuse AOM with otitis externa (swimmer’s ear) — different aetiology and treatment.
Dose adjustment: Renal → Part 4.

PRIMARY INDICATION 5: Oral Step-Down from IV Cefazolin (Cross-Indication)

ℹ️ This is one of the most valuable clinical applications of cephalexin — as the oral continuation of IV cefazolin therapy. Both are first-generation cephalosporins with an overlapping spectrum. This IV-to-oral switch is pharmacologically rational and widely practised.

Common clinical scenarios for cefazolin → cephalexin step-down:

Original IV Indication	Cephalexin Step-Down Dose	Duration of Oral Phase	Notes
SSTI (MSSA) treated with IV cefazolin	500 mg q8h or q6h	Complete total 7–14 day course	Standard step-down. Switch when afebrile ≥24–48 h, clinically improving, tolerating oral.
Surgical prophylaxis extension (rare — prophylaxis should be ≤24 h)	500 mg q8h	Only if post-operative wound infection develops → treat the infection, not the prophylaxis	⚠️ Extending surgical prophylaxis beyond 24 hours with oral cephalexin is NOT recommended as “prophylaxis continuation” — it is either unnecessary (no infection) or constitutes treatment (infection present).
Post-operative wound infection (MSSA)	500 mg q6–8h	7–14 days total (IV + oral)	Directed therapy based on wound culture.
Bacteraemia (MSSA — uncomplicated, source controlled)	500 mg–1 g q6h	Complete total course (2–4 weeks for MSSA bacteraemia) — specialist decision	⚠️ Oral step-down for MSSA bacteraemia is a specialist decision. Some ID specialists use cephalexin 1 g q6h; others prefer cloxacillin or flucloxacillin for higher potency. Evidence base for oral step-down in SAB remains evolving.
Osteomyelitis / Septic arthritis (MSSA)	1 g q6h (high-dose oral)	3–6 weeks oral phase (after initial IV phase — see below)	See Primary Indication 6.

IV-to-oral switch criteria (universal):
All of the following should be met before switching IV cefazolin → oral cephalexin:

✔ Afebrile for ≥24–48 hours
✔ Clinical improvement (local signs improving, WBC trending down, CRP declining)
✔ Haemodynamically stable
✔ Tolerating oral intake and medications
✔ No concern for deep-seated undrained collection
✔ Culture confirms susceptible organism (if available)
✔ Reliable patient for oral adherence (or caregiver available)

Mandatory Clinical Notes Checklist — IV-to-Oral Step-Down:

When to prefer: This switch is appropriate for virtually ALL indications where IV cefazolin was used for MSSA/streptococcal infections once the patient meets switch criteria. The pharmacological consistency (both first-generation cephalosporins) and cephalexin’s high oral bioavailability (~90–95%) make this a rational and evidence-supported transition.
When NOT to use: ⛔ Endocarditis (IV therapy for full duration); ⛔ Meningitis (poor CSF penetration); ⛔ Patient cannot tolerate oral medications (vomiting, ileus); ⛔ Organism is resistant to cephalexin but was susceptible to cefazolin at a higher dose (rare — but check culture).
NLEM status: ✔ Both cefazolin and cephalexin on NLEM.
Time to response: Already responding (switch occurs AFTER response to IV therapy).
Treatment failure after switch: Recurrence of fever/symptoms after switching to oral → consider: (a) inadequate oral absorption (vomiting? diarrhoea?), (b) undrained collection, © organism resistance not detected, (d) need to return to IV.
Mandatory baseline: Culture confirmation of susceptible organism (RECOMMENDED before switch). Clinical assessment of readiness for oral switch.
Specialist initiation: For straightforward SSTI — primary care can manage the switch. For bacteraemia, osteomyelitis, endocarditis follow-on → ID specialist decision.
Indian guideline source: API Textbook; AIIMS Antibiotic Policy; ICMR guidelines support IV-to-oral switch for appropriate infections.
Key safety warning: ⚠️ Ensure the patient actually takes the oral antibiotic reliably. The advantage of cephalexin (food-independent, TDS dosing) should be leveraged for adherence. Provide a clear written prescription and follow-up plan.
Dose adjustment: Per renal function.

PRIMARY INDICATION 6: Bone and Joint Infections — MSSA (Oral Step-Down / Suppressive Therapy)

ℹ️ Cephalexin is used for the oral continuation phase of MSSA osteomyelitis and septic arthritis treatment, following an initial IV phase (typically IV cefazolin or nafcillin/cloxacillin). This is a high-dose oral application — cephalexin doses of 1 g q6h (4 g/day) are used, significantly higher than standard SSTI doses.

Dosing — Osteomyelitis / Septic Arthritis (Oral Phase):

Phase	Dose	Frequency	Maximum	Duration	Notes
IV phase (initial)	IV cefazolin 1–2 g q8h (NOT cephalexin — no IV formulation)	q8h IV	Per cefazolin dosing	5–7 days minimum (longer for complicated cases)	Switch to oral when clinically improving, CRP declining, afebrile ≥48 h.
Oral step-down	Cephalexin 1 g	q6h (QDS)	Max 1 g per dose; Max 4 g/day	3–6 weeks (total IV + oral = 4–6 weeks for acute osteomyelitis)	⚠️ HIGH-DOSE oral therapy. 4 g/day is the maximum. Some experts use 750 mg q6h (3 g/day) for patients who tolerate the high dose poorly.
Chronic suppressive therapy (select cases — prosthetic joint infection, chronic osteomyelitis where cure not achievable)	500 mg	q8h (TDS) or q6h (QDS)	Max 500 mg per dose; Max 2 g/day	Months to lifelong — specialist decision	⚠️ Specialist (orthopaedics + ID) decision only. Regular monitoring (renal function, LFT, CBC) required for prolonged courses.

Duration — Bone and Joint Infections:

Condition	Total Duration (IV + Oral)
Acute osteomyelitis (adult)	4–6 weeks
Chronic osteomyelitis	6 weeks to 3 months (+ surgical debridement)
Vertebral osteomyelitis	6–8 weeks (longer with complications)
Septic arthritis (native joint)	3–4 weeks
Prosthetic joint infection — suppressive therapy	Months to lifelong

⚠️ OVIVA trial context: The OVIVA trial (Li et al., NEJM 2019) demonstrated non-inferiority of early oral step-down for bone and joint infections. While the trial predominantly used flucloxacillin as the oral anti-staphylococcal agent, cephalexin 1 g q6h is an acceptable alternative — especially in India where flucloxacillin availability is limited. Some Indian ID specialists specifically prefer cephalexin for its superior oral bioavailability (~90–95%) and food-independent absorption compared to cloxacillin (~37–50%, empty-stomach requirement).

Mandatory Clinical Notes Checklist — Bone & Joint Infections:

When to prefer cephalexin: Oral step-down from IV cefazolin for MSSA osteomyelitis/septic arthritis. Preferred over cloxacillin for oral step-down when adherence to empty-stomach q6h dosing is unreliable. Preferred when flucloxacillin is unavailable (common in India). High oral bioavailability (~90–95%) achieves reliable serum levels.
When NOT to use: ⛔ MRSA bone/joint infection; ⛔ Polymicrobial osteomyelitis (e.g., post-compound fracture, diabetic foot — need broader coverage); ⛔ TB spondylitis (must be excluded in India — very high prevalence); ⛔ Fungal osteomyelitis (immunocompromised).
NLEM status: ✔ On NLEM.
Time to response: CRP should decline within 1 week. Pain improvement within 5–7 days.
Treatment failure: Rising CRP after initial decline; persistent fever; new imaging abnormalities → reassess (repeat cultures, imaging, surgical re-evaluation).
Mandatory baseline: Blood cultures (MANDATORY); bone biopsy culture (RECOMMENDED — gold standard); CRP + ESR (for monitoring); MRI (imaging of choice); renal function.
Specialist initiation: ⚠️ MANDATORY. Bone and joint infections must be managed by orthopaedics and/or ID specialist. Oral step-down dose and duration are specialist decisions.
Indian guideline source: API Textbook; AIIMS Antibiotic Policy; OVIVA trial (international — increasingly adopted in Indian practice).
Key safety warning: ⚠️ At 4 g/day dosing for osteomyelitis, GI side effects (nausea, diarrhoea) are more common. Monitor renal function weekly during prolonged courses. ⚠️ Always exclude TB osteomyelitis in India before starting prolonged anti-staphylococcal therapy.
Dose adjustment: Renal impairment — see Part 4 (important at high-dose 4 g/day regimen). Elderly → always check eGFR.

Secondary Indications — Adults Only (Off-label, if any)

SECONDARY INDICATION 1: Dental Infections (Periapical Abscess, Dental Cellulitis)

OFF-LABEL (not specifically labelled on many CDSCO product inserts, though some include “dental infections” broadly)

OFF-LABEL but accepted standard practice in India — used by dentists and general practitioners for dental infections when amoxicillin cannot be used.

ℹ️ The standard first-line antibiotic for odontogenic infections in India is amoxicillin (500 mg q8h) or amoxicillin-clavulanate (625 mg q8h) — because dental infections are often polymicrobial (streptococci + oral anaerobes). Cephalexin provides good streptococcal coverage but lacks anaerobic activity — limiting its usefulness as monotherapy for deep dental infections with an anaerobic component.

Dosing: 500 mg q8h × 5–7 days

When to use cephalexin for dental infections:

Non-anaphylactic penicillin allergy (when amoxicillin/amoxicillin-clavulanate cannot be used)
Superficial dental cellulitis without deep-space involvement (streptococcal predominant)
In combination with metronidazole 400 mg q8h for mixed aerobic-anaerobic coverage

Evidence basis: Dental practice guidelines (Indian Dental Association; ADA guidelines). Expert consensus.

Level of evidence quality: Weak — consensus/expert practice. No RCTs comparing cephalexin to amoxicillin specifically for dental infections.

Specialist only: Not required — can be prescribed by dentists and GPs.

SECONDARY INDICATION 2: Infective Endocarditis Prophylaxis — Dental Procedures (Penicillin-Allergic Patients)

OFF-LABEL for many Indian product inserts, but accepted standard practice — endorsed by AHA/ESC guidelines, widely followed in India.

ℹ️ The standard first-line agent for IE dental prophylaxis is amoxicillin 2 g oral, 30–60 minutes before the procedure (single dose). For patients with non-anaphylactic penicillin allergy, cephalexin 2 g oral is the recommended alternative.

Dosing:

Dose	Timing	Duration	Notes
2 g oral (single dose)	30–60 minutes before dental procedure (preferred timing: 60 minutes before)	Single dose only (no post-procedural dose needed)	⛔ Do NOT use in patients with history of penicillin anaphylaxis — use azithromycin 500 mg or clindamycin 600 mg instead. For non-anaphylactic penicillin allergy (e.g., rash), cephalexin is acceptable (~1–2% cross-reactivity).

Indications for IE prophylaxis (which patients need prophylaxis before dental procedures):

Prosthetic cardiac valve or prosthetic material for valve repair
Previous infective endocarditis
Congenital heart disease (unrepaired cyanotic CHD, repaired with residual defects, within 6 months of repair)
Cardiac transplant recipients with valvulopathy

⚠️ Rheumatic heart disease and IE prophylaxis in India: The role of IE prophylaxis for patients with rheumatic valvular disease undergoing dental procedures is debated. AHA/ESC guidelines no longer recommend routine prophylaxis for native valve RHD (only for the conditions listed above). However, some Indian cardiologists and the API Textbook continue to recommend prophylaxis for patients with significant rheumatic valvular lesions (moderate-severe mitral regurgitation, aortic stenosis). This is an area where Indian practice may diverge from AHA/ESC. Follow institutional protocol and the treating cardiologist’s recommendation.

Evidence basis: AHA IE Prophylaxis Guidelines (Wilson et al., 2007/2021 update); ESC IE Guidelines (2015/2023 update); API Textbook of Medicine.

Level of evidence quality: Moderate — guideline-endorsed (AHA/ESC), though the overall benefit of IE dental prophylaxis is debated (no RCTs).

Specialist only: Cardiologist should identify patients who need prophylaxis; prescribing of the prophylactic dose can be done by dentist or GP.

SECONDARY INDICATION 3: Recurrent UTI Prophylaxis (Antibiotic Prophylaxis)

OFF-LABEL for most product inserts.

OFF-LABEL but accepted standard practice — used in Indian urology and gynaecology practice.

ℹ️ For women with recurrent uncomplicated UTI (≥3 episodes in 12 months or ≥2 in 6 months), low-dose prophylaxis is a well-established prevention strategy. Nitrofurantoin is the preferred first-line prophylactic agent (ICMR, IDSA). Cephalexin is an alternative when nitrofurantoin is contraindicated (eGFR <30) or not tolerated.

Dosing:

Strategy	Dose	Frequency	Duration	Notes
Continuous prophylaxis	125–250 mg	Once daily at bedtime	6–12 months	Lower dose than therapeutic (prophylactic only). At bedtime to maximise overnight urinary concentration.
Post-coital prophylaxis	250 mg	Single dose within 2 hours after sexual intercourse	As needed	For women with UTI clearly associated with sexual intercourse.

Evidence basis: IDSA/ESCMID guidelines on recurrent UTI; multiple RCTs supporting low-dose prophylaxis with various agents including cephalexin; Indian urology/urogynaecology practice.

Level of evidence quality: Strong — multiple RCTs support low-dose cephalosporin prophylaxis for recurrent UTI (though nitrofurantoin is better studied as the preferred agent).

Specialist only: Urology or gynaecology guidance recommended for initiation. Primary care can continue the regimen.

SECONDARY INDICATION 4: Acne Vulgaris — Moderate (Alternative Oral Antibiotic)

OFF-LABEL

ℹ️ Standard first-line oral antibiotics for acne in India are doxycycline and minocycline (tetracyclines). Cephalexin is used as an alternative when tetracyclines are contraindicated (pregnancy, children <8 years, allergy) or poorly tolerated.

Dosing: 500 mg q12h (BD) × 3 months (typical course — re-evaluate at 3 months)

Duration: 3–6 months. Do NOT exceed 6 months of continuous antibiotic therapy for acne (AMR stewardship).

Evidence basis: Observational studies; dermatology specialist practice; AAD (American Academy of Dermatology) guidelines list cephalexin as a second-line option. Indian dermatology textbooks reference cephalexin as an alternative.

Level of evidence quality: Weak — no RCTs comparing cephalexin to tetracyclines for acne. Expert consensus/observational data.

Specialist only: Dermatologist guidance recommended for acne requiring oral antibiotics.

SECONDARY INDICATION 5: Lactational Mastitis (Infective)

OFF-LABEL (not specifically labelled on most product inserts)

OFF-LABEL but accepted standard practice — used in Indian obstetric practice.

ℹ️ S. aureus is the most common cause of infective lactational mastitis. Cephalexin provides effective MSSA coverage and is safe during breastfeeding (low milk excretion, safe for infant).

Dosing: 500 mg q6–8h × 7–10 days

When to start antibiotics for mastitis: Symptoms not improving after 12–24 hours of conservative measures (frequent feeding, warm compresses) OR moderate-severe symptoms at presentation (erythema >3 cm, fever >38.5°C, systemic illness).

Compatibility with breastfeeding: ✔ Yes — cephalexin is safe during breastfeeding. Continued breastfeeding from the affected breast is encouraged.

Evidence basis: WHO Mastitis Guidelines; obstetric/gynaecology textbooks; IAP breastfeeding guidelines.

Level of evidence quality: Strong — WHO guideline-endorsed; widespread clinical practice.

Specialist only: Not required — can be initiated by GP/obstetrician/paediatrician.

SECONDARY INDICATION 6: UTI in Pregnancy (Second-Line Agent)

OFF-LABEL for some product inserts (some include UTI broadly)

OFF-LABEL but accepted standard practice in India — commonly used in Indian obstetric practice.

ℹ️ First-line for UTI in pregnancy is nitrofurantoin (100 mg BD × 5–7 days — avoid in third trimester near term and in G6PD deficiency) or amoxicillin-clavulanate (if susceptible). Cephalexin is a widely used second-line alternative — safe in all trimesters, well-tolerated.

Dosing: 500 mg q6–8h × 7 days (for symptomatic UTI/cystitis in pregnancy)

For asymptomatic bacteriuria (ASB) in pregnancy: Same dose, 3–7 days. ⚠️ Screening and treating ASB in pregnancy is MANDATORY (ICMR, FOGSI) — untreated ASB increases pyelonephritis risk.

Evidence basis: FOGSI guidelines; ICMR; WHO; ACOG. Cephalexin is classified as safe in pregnancy (former FDA Category B).

Level of evidence quality: Moderate — limited RCTs specific to cephalexin in pregnancy UTI, but extensive clinical experience and guideline endorsement.

Specialist only: Not required — can be prescribed by obstetrician or GP managing antenatal care.

PAEDIATRIC DOSING (Specialist Only)

General Notes:

⚠️ All paediatric dosing below is for clinician use only — doses must be calculated and verified by the treating physician or clinical pharmacist before administration.
Minimum age: Cephalexin can be used from 1 month of age onwards for standard labelled indications. Use in neonates (<28 days) is off-label but practised under neonatologist supervision (see Neonatal Dosing subsection below).
Minimum weight: No absolute minimum weight. Weight-based dosing (mg/kg) applies. For neonates <2 kg, dosing data is very limited — specialist guidance essential.
Dosing method: Weight-based (mg/kg/day divided into doses) — preferred for all paediatric age groups.
Dosing convention:
- Doses are expressed as mg/kg/day (total daily dose) divided into 2, 3, or 4 doses — OR as mg/kg/dose with frequency specified
- This monograph uses mg/kg/dose with frequency for clarity
Maximum absolute dose (adult ceiling): Regardless of the child’s weight, do NOT exceed adult maximum doses:
- Standard infections: Max 500 mg per dose; Max 2 g per day
- Serious infections (osteomyelitis step-down): Max 1 g per dose; Max 4 g per day
Adolescent transition: Children ≥12 years AND ≥40 kg → use adult dosing. If the adolescent weighs <40 kg despite being ≥12 years, continue weight-based dosing.

Formulation suitability for children:

✔ Dry syrup / Oral suspension (125 mg/5 mL, 250 mg/5 mL): The primary formulation for paediatric use. Widely available across India from multiple manufacturers. Reconstitute with water before use (see Reconstitution section below).
- ⚠️ Palatability: Cephalexin suspension has a mildly sweet, fruity flavour (most manufacturers add flavouring — strawberry, orange, or mixed-fruit). It is significantly more palatable than cloxacillin suspension (which is notoriously bitter). This is a meaningful practical advantage for paediatric adherence.
- ℹ️ Palatability varies by manufacturer — some brands taste better than others. Parents/caregivers should be counselled that the child may initially resist the taste but can usually be given the medicine mixed with a small amount of juice or sweetened drink immediately before administration (unlike cloxacillin/flucloxacillin, which cannot be mixed with food due to absorption concerns — cephalexin has no food-effect restriction).
- ✔ Can be administered via nasogastric tube — shake well, draw up measured dose with oral syringe, flush tube with 5–10 mL water before and after.
✔ Paediatric drops (125 mg/1.25 mL = 100 mg/mL): For infants and very young children where smaller volumes are preferred. Limited availability from select manufacturers — not all pharmacies stock this formulation. If unavailable, use the standard oral suspension (125 mg/5 mL) with a calibrated oral syringe for accurate small-volume dosing.
✔ Capsules (250 mg, 500 mg): For older children (typically ≥8–10 years) who can swallow capsules whole. Capsules should be swallowed intact with water. If a child cannot swallow capsules, the capsule may be opened and contents mixed with a small amount of soft food (jam, yogurt, applesauce) — unlike cloxacillin, cephalexin absorption is NOT impaired by food. However, the powder is somewhat gritty and may have a mild bitter taste — mix thoroughly and consume immediately. This is an off-label administration method but widely practised.
✔ Dispersible tablets (250 mg, 500 mg — select manufacturers): Can be dispersed in a small volume of water (10–20 mL) for children who cannot swallow tablets. Suitable for enteral tube administration. Limited availability in India.

Age-specific pharmacokinetic differences affecting dosing:

Age Group	PK Considerations
Neonates (0–28 days)	Immature renal function → prolonged half-life (3–5 hours vs ~1 hour in older children/adults). Higher Vd per kg (larger extracellular water compartment). Oral absorption may be erratic in neonates <2 weeks of age — bioavailability less predictable than in older infants. Dosing interval must be extended to q8–12h rather than q6–8h.
Infants (1–12 months)	Renal function matures rapidly over the first 3–6 months. By 6 months, GFR per BSA approaches adult values. Standard q8h dosing interval applies from ~1 month of age. Oral absorption is generally reliable from ~1 month of age.
Young children (1–5 years)	Per-kg clearance is higher than adults → children may need the upper end of the weight-based dose range. Standard q8h dosing. Oral suspension is the appropriate formulation — most children in this age group cannot swallow capsules.
Children (6–12 years)	PK approaches adult values. Standard weight-based dosing with q8h (or q6h for serious infections) interval. Many children ≥8 years can attempt capsule formulation.
Adolescents ≥12 years (≥40 kg)	Use adult dosing.

Safety monitoring requirements specific to paediatric use:

Monitor for GI intolerance (diarrhoea, nausea, vomiting) — the most common adverse effects; usually mild and self-limiting
For prolonged courses (>2 weeks): monitor CBC, renal function at baseline and periodically
⚠️ Oral candidiasis (thrush): Common in young children and infants on oral cephalexin courses >7 days. Inspect oral cavity; treat with nystatin oral drops if symptomatic.
⚠️ Nappy/diaper candidiasis: Common in infants. Treat with topical clotrimazole or nystatin cream.
⚠️ Antibiotic-associated diarrhoea (AAD): More common in children than adults. Usually mild. If severe, bloody, or accompanied by fever → evaluate for CDI (uncommon in young children but possible, especially in hospitalised paediatric patients).
For cephalexin’s favourable safety profile, routine laboratory monitoring is NOT necessary for standard short courses (5–10 days) in otherwise healthy children.

NEONATAL DOSING (Separate Subsection)

⚠️ Neonatal use — specialist supervision only (neonatologist / paediatrician).

Status: Cephalexin use in neonates is off-label for most Indian product inserts (which typically state “use in children >1 month”). However, cephalexin is used in neonates in clinical practice, supported by pharmacokinetic data and international neonatal references.

Indications in neonates: Late-onset neonatal UTI (oral treatment or step-down from IV); neonatal skin infections (mild-moderate, MSSA — oral therapy when IV not required); UTI prophylaxis in neonates with urinary tract anomalies (specialist-directed).

ℹ️ For neonatal sepsis (early-onset or late-onset), parenteral therapy is standard — ampicillin + gentamicin for EONS; IV cefazolin, cloxacillin, or vancomycin + aminoglycoside for LONS. Cephalexin’s role in neonates is limited to oral step-down or outpatient therapy for confirmed susceptible infections after initial parenteral stabilisation.

Neonatal Dosing Table — Cephalexin Oral:

Postnatal Age	Dose	Frequency	Maximum Daily Dose	Notes
0–7 days (term)	12.5 mg/kg/dose	q12h	25 mg/kg/day	Immature renal clearance. Longest dosing interval. Oral absorption may be erratic — use parenteral therapy preferentially in this age group.
8–28 days (term)	12.5–25 mg/kg/dose	q8h	75 mg/kg/day	Renal maturation allows shorter interval. 25 mg/kg/dose for moderate infections.
Preterm neonates	12.5 mg/kg/dose	q12h (regardless of postnatal age for the first 2–4 weeks)	25 mg/kg/day	Very limited data. Use only under specialist supervision. Prefer parenteral agents when feasible.

Formulation for neonates: Use the paediatric drops (100 mg/mL) if available — allows small accurate volumes. If drops unavailable, use the oral suspension (125 mg/5 mL = 25 mg/mL) with a calibrated oral syringe.

ℹ️ Source for neonatal dosing: NNF India Drug Doses handbook (limited data for cephalexin specifically — neonatal dosing extrapolated from PK principles); Neofax (international neonatal drug reference — used as supportive source); Paediatric & Neonatal Dosage Handbook (Lexicomp — factual dosing data referenced, not text).

Primary Indications — Paediatric (Approved / Standard in India)

PAEDIATRIC PRIMARY INDICATION 1: Skin and Soft Tissue Infections (SSTI) — MSSA / Streptococcal

ℹ️ This is the most common paediatric indication for cephalexin in India. Impetigo, infected eczema, insect bite cellulitis, minor wound infections, and folliculitis are extremely common in Indian children.

Weight-Based Dosing Table:

Severity	Dose	Frequency	Max Per-Dose / Max Daily	Duration	Notes
Mild SSTI (localised impetigo, small infected wound, folliculitis)	12.5 mg/kg/dose	q8h (TDS)	Max 250 mg per dose; Max 750 mg/day	5–7 days	For limited impetigo, topical mupirocin or fusidic acid may be adequate alone. Cephalexin for extensive or topical-failure cases.
Moderate SSTI (spreading cellulitis without systemic signs, larger infected wound, bullous impetigo, furuncle)	25 mg/kg/dose	q8h (TDS)	Max 500 mg per dose; Max 1.5 g/day	5–7 days	Most common paediatric prescription.
Severe SSTI (cellulitis with systemic signs, large abscess post-drainage with surrounding cellulitis)	25 mg/kg/dose	q6h (QDS)	Max 500 mg per dose; Max 2 g/day	7–10 days	Consider IV cefazolin for children with systemic signs (high fever, unable to tolerate oral).

Age-Bracket Dosing Guide (for quick reference when weight is not immediately available):

Age Group	Approximate Weight Range	Typical Dose (Moderate SSTI)	Volume of 125 mg/5 mL Suspension	Volume of 250 mg/5 mL Suspension
1–12 months	4–10 kg	100–250 mg/day divided TDS	1.5–3.5 mL per dose	0.7–1.7 mL per dose
1–3 years	10–15 kg	250–375 mg/day divided TDS	3.5–5 mL per dose	1.7–2.5 mL per dose
3–6 years	15–20 kg	375–500 mg/day divided TDS	5–6.5 mL per dose	2.5–3.3 mL per dose
6–12 years	20–40 kg	500 mg–1 g/day divided TDS	Use capsules if able to swallow	Use 250 mg/5 mL suspension or capsules
≥12 years (≥40 kg)	≥40 kg	Adult dosing	Capsules / tablets	—

⚠️ Always verify by calculating weight-based dose — age-bracket dosing is approximate and should only be used as a quick-reference when exact weight measurement is temporarily unavailable.

Clinical Notes — Paediatric SSTI:

Impetigo in Indian children is overwhelmingly due to S. aureus (MSSA) and/or S. pyogenes (GAS) — both well-covered by cephalexin
For simple, small impetigo lesions (<3 lesions, limited area): topical mupirocin 2% or fusidic acid 2% applied TDS for 5 days may suffice without oral antibiotics
Screen for scabies in children presenting with secondary bacterial infection of skin — treat scabies concomitantly (permethrin 5% cream)
⚠️ In India, community-acquired MRSA (CA-MRSA) in children is increasingly reported, particularly in urban settings. If SSTI fails to respond to cephalexin at 72 hours, or if the child has recurrent abscesses → obtain wound culture → consider TMP-SMX or clindamycin for CA-MRSA
IAP guidelines recommend first-generation cephalosporins (cephalexin) as acceptable first-line oral agents for MSSA SSTI in children

PAEDIATRIC PRIMARY INDICATION 2: Acute Pharyngitis / Tonsillitis — Group A Streptococcus (GAS)

ℹ️ This is one of the most important paediatric indications for cephalexin in India. GAS pharyngitis is predominantly a paediatric disease (peak age 5–15 years). Adequate treatment prevents acute rheumatic fever (ARF) and rheumatic heart disease (RHD) — India has the highest RHD burden globally.

Weight-Based Dosing Table:

Dose	Frequency	Max Per-Dose / Max Daily	Duration	Notes
20 mg/kg/dose	q12h (BD)	Max 500 mg per dose; Max 1 g/day	10 days — MUST complete full course	⚠️ BD dosing is evidence-supported for GAS pharyngitis (Pichichero et al., 2000) and significantly improves adherence in children. Full 10-day course is non-negotiable for ARF prevention.

Alternative dosing: 12.5–25 mg/kg/dose q8h (TDS) for 10 days — if BD dosing is not preferred by the treating physician. Total daily dose range: 25–50 mg/kg/day.

ℹ️ First-line remains amoxicillin: IAP guidelines and WHO recommend amoxicillin (50 mg/kg/day in 2 divided doses, or 25 mg/kg BD, max 1 g/day) × 10 days as first-line for GAS pharyngitis in children. Cephalexin is an acceptable alternative with equivalent bacteriological eradication rates.

When to use cephalexin over amoxicillin for paediatric GAS pharyngitis:

Non-anaphylactic penicillin allergy
Treatment failure with amoxicillin (persistent symptoms or positive throat culture after completing amoxicillin course)
Recurrent GAS pharyngitis (some evidence of superior bacteriological eradication with cephalosporins in recurrence — Casey & Pichichero meta-analysis, 2007)
BD cephalexin may improve adherence in school-going children compared to TDS amoxicillin (though amoxicillin also supports BD dosing)

Clinical Notes — Paediatric GAS Pharyngitis:

⚠️ Full 10-day course is essential. Indian parents frequently stop antibiotics when the child feels better (usually day 2–3). This is the single biggest barrier to ARF prevention. Counsel emphatically at the time of prescribing.
Use the Modified Centor / McIsaac Score to assess clinical probability of GAS pharyngitis — do NOT prescribe antibiotics for probable viral pharyngitis
RADT (rapid antigen detection test for GAS) is increasingly available at some Indian paediatric clinics — use if available to confirm diagnosis
In resource-limited settings without RADT/throat culture: Treat clinically based on McIsaac score ≥3 (especially in children with high fever, tonsillar exudate, tender anterior cervical lymphadenopathy, absence of cough)
Rheumatic fever prophylaxis: Cephalexin is NOT used for secondary ARF prophylaxis (benzathine penicillin G injection every 3–4 weeks is the standard). Cephalexin is only for treatment of acute GAS pharyngitis (primary prevention of ARF).

PAEDIATRIC PRIMARY INDICATION 3: Urinary Tract Infections (Paediatric)

Weight-Based Dosing Table — Paediatric UTI:

Indication	Dose	Frequency	Max Per-Dose / Max Daily	Duration	Notes
Acute cystitis (lower UTI)	12.5–25 mg/kg/dose	q8h (TDS)	Max 500 mg per dose; Max 1.5 g/day	3–5 days (IAP guidelines accept 3-day course for uncomplicated paediatric cystitis >2 years; 5–7 days for younger children)	Second-line agent. First-line: nitrofurantoin or TMP-SMX (if susceptible). Obtain urine culture before starting.
Acute pyelonephritis (mild, oral step-down)	25 mg/kg/dose	q8h (TDS) or q6h (QDS)	Max 500 mg per dose; Max 2 g/day	10–14 days total (IV → oral step-down)	Oral cephalexin is used for step-down from IV cefazolin/ceftriaxone after initial improvement. NOT for empiric pyelonephritis in sick children (use IV).
UTI prophylaxis (vesicoureteric reflux, recurrent UTI)	5–10 mg/kg/dose	Once daily at bedtime	Max 250 mg per dose	Months to years — specialist (paediatric nephrologist/urologist) decision	Low-dose prophylaxis. Alternative to nitrofurantoin and TMP-SMX. Used when other agents not tolerated.

Clinical Notes — Paediatric UTI:

⚠️ Urine culture is MANDATORY in all paediatric UTI (IAP guidelines) — unlike adult uncomplicated cystitis where empiric therapy without culture is sometimes acceptable. Paediatric UTI requires imaging workup (USG KUB at minimum) for structural abnormalities, especially first episode in children <2 years.
Method of urine collection matters: Bag urine specimens have high contamination rates → suprapubic aspiration (gold standard in infants) or catheter specimen for young children; midstream clean-catch for toilet-trained children
In India, community-acquired E. coli resistance to cephalexin in paediatric UTI is ~30–45% — always send culture and adjust therapy accordingly
Enterococcal UTI in children (not uncommon, especially in those with structural abnormalities) → cephalexin has NO enterococcal activity → use amoxicillin
IAP UTI guidelines recommend cephalexin as a second-line option for acute paediatric UTI treatment and as an option for UTI prophylaxis

PAEDIATRIC PRIMARY INDICATION 4: Acute Otitis Media (AOM)

ℹ️ AOM is predominantly a paediatric disease (peak age 6 months – 3 years). Amoxicillin is the undisputed first-line (80–90 mg/kg/day divided q8–12h × 10 days for children <2 years; 5–7 days for older children). Cephalexin is a second-line alternative with the important caveat of borderline H. influenzae coverage.

Weight-Based Dosing Table:

Dose	Frequency	Max Per-Dose / Max Daily	Duration	Notes
25 mg/kg/dose	q8h (TDS)	Max 500 mg per dose; Max 1.5 g/day	10 days (<2 years or severe); 5–7 days (≥2 years, mild-moderate)	Second-line only. Amoxicillin-clavulanate or cefuroxime axetil preferred as second-line for AOM (better H. influenzae coverage). Cephalexin only when these alternatives are unavailable or not tolerated.

Clinical Notes — Paediatric AOM:

IAP guidelines and AAP guidelines both recommend amoxicillin as first-line
For treatment failure at 48–72 hours with amoxicillin → switch to amoxicillin-clavulanate (not cephalexin) — the failure is often due to H. influenzae or beta-lactamase-producing M. catarrhalis, which cephalexin covers poorly
Cephalexin’s role in paediatric AOM is limited — primarily for children with non-anaphylactic penicillin allergy when amoxicillin-clavulanate and cefuroxime axetil are also unavailable
Observation without antibiotics (“watchful waiting”) is an option for mild AOM in children ≥2 years with unilateral disease — discuss with parents

PAEDIATRIC PRIMARY INDICATION 5: Bone and Joint Infections — MSSA (Oral Phase, Paediatric)

ℹ️ Paediatric acute haematogenous osteomyelitis and septic arthritis are among the most important serious paediatric infections. Early oral step-down (after 3–7 days of IV therapy) is well-supported by evidence in uncomplicated paediatric bone/joint infections (Peltola et al., 2009, 2010 — Finnish RCTs).

Weight-Based Dosing Table:

Phase	Dose	Frequency	Max Per-Dose / Max Daily	Duration	Notes
IV phase	IV cefazolin 25–50 mg/kg/dose q8h (NOT cephalexin)	q8h IV	Per cefazolin dosing	3–7 days minimum (until clinical improvement, CRP declining, afebrile)	Switch to oral when clinically improving.
Oral step-down	Cephalexin 25–37.5 mg/kg/dose (some protocols use up to 50 mg/kg/dose for osteomyelitis)	q6–8h	Max 1 g per dose; Max 4 g/day	Complete total course: 3–4 weeks for uncomplicated osteomyelitis; 2–3 weeks for septic arthritis (shorter courses supported in paediatrics)	High-dose oral therapy. Monitor adherence carefully.

Clinical Notes — Paediatric Bone/Joint:

Cephalexin is an excellent oral step-down agent after IV cefazolin for paediatric MSSA osteomyelitis/septic arthritis
IAP guidelines and the Finnish paediatric osteomyelitis RCTs (Peltola et al.) support:
- Short IV courses (3–5 days) followed by oral step-down
- Shorter total courses (3–4 weeks for uncomplicated osteomyelitis; 2–3 weeks for septic arthritis) than traditionally used
- Serial CRP is the best monitoring marker — CRP should decline by >50% from peak before oral switch and continue declining during oral therapy
⚠️ In children <5 years, Kingella kingae is an important pathogen for bone/joint infections — NOT well covered by cephalexin → use amoxicillin-clavulanate if Kingella is suspected
⚠️ Always exclude TB osteomyelitis in India — histopathology/GeneXpert from bone biopsy
Cephalexin’s food-independent absorption and palatable suspension formulation make it an ideal oral step-down agent for paediatric bone infections — superior adherence profile compared to cloxacillin (which requires empty-stomach q6h dosing and has a bitter-tasting suspension)

Secondary Indications — Paediatric (Off-label, if any)

PAEDIATRIC SECONDARY INDICATION 1: UTI Prophylaxis in Children with Vesicoureteric Reflux (VUR)

OFF-LABEL for most product inserts (continuous low-dose prophylaxis is not a standard labelled indication)

OFF-LABEL but accepted standard practice — endorsed by IAP Nephrology Chapter, Indian Society of Paediatric Nephrology (ISPN), and international guidelines (AAP VUR guidelines).

Dosing:

5–10 mg/kg/dose oral, once daily at bedtime
Max 250 mg per dose
Duration: months to years (until VUR resolves or surgical correction — specialist decision)

When to use cephalexin for UTI prophylaxis in VUR:

First-line prophylactic agents: nitrofurantoin (1–2 mg/kg OD) or TMP-SMX (1–2 mg/kg TMP OD)
Cephalexin is an alternative when nitrofurantoin/TMP-SMX is not tolerated, contraindicated, or the organism is resistant
Preferred in neonates and young infants <2 months (nitrofurantoin is contraindicated in first month; TMP-SMX should be avoided in first 6 weeks due to kernicterus risk)

Evidence basis: AAP VUR Guidelines (2011); RIVUR Trial (NEJM 2014 — antimicrobial prophylaxis reduces UTI recurrence in VUR); IAP/ISPN guidelines.

Level of evidence quality: Strong — RCT evidence (RIVUR) supports prophylaxis for Grade III–V VUR. Cephalexin specifically is one of the accepted agents.

Specialist only: Yes — paediatric nephrologist or urologist should initiate and monitor.

PAEDIATRIC SECONDARY INDICATION 2: Infective Endocarditis Prophylaxis — Dental Procedures (Paediatric)

OFF-LABEL — but accepted standard practice per AHA/ESC guidelines, widely followed in India.

Dosing (paediatric):

50 mg/kg oral (single dose), 30–60 minutes before dental procedure
Max dose: 2 g (adult ceiling)

Indications: Same as adult IE prophylaxis indications (see Part 2 — prosthetic valves, prior IE, certain CHD, transplant valvulopathy).

⚠️ Indian paediatric context: Many Indian children have repaired or unrepaired congenital heart disease and are followed in paediatric cardiology clinics. The paediatric cardiologist should clearly document in the child’s health records whether IE prophylaxis is required before dental procedures, and which antibiotic should be used. This information should be communicated to the family and to the child’s dentist.

⛔ Do NOT use cephalexin for IE prophylaxis in children with history of penicillin anaphylaxis → use azithromycin (15 mg/kg, max 500 mg, single dose before procedure) or clindamycin (20 mg/kg, max 600 mg).

Evidence basis: AHA IE Prophylaxis Guidelines; IAP Cardiology Chapter guidelines.

Level of evidence quality: Moderate — guideline-endorsed; no paediatric-specific RCTs for IE prophylaxis.

Specialist only: Paediatric cardiologist identifies which children need prophylaxis. Prescription of the prophylactic dose can be by the cardiologist, dentist, or paediatrician.

PAEDIATRIC SECONDARY INDICATION 3: Acne Vulgaris — Adolescent (Alternative Oral Antibiotic)

OFF-LABEL

Dosing: 500 mg q12h (BD) × 3 months (in adolescents ≥12 years / ≥40 kg — use adult dosing)

When to use: Only when tetracyclines (doxycycline, minocycline) are contraindicated:

Children <8 years (tetracyclines contraindicated due to dental staining)
In practice, acne requiring oral antibiotics in children <8 years is uncommon — if needed, specialist (dermatologist) guidance essential
In adolescents ≥12 years who cannot tolerate tetracyclines

Evidence basis: Dermatology specialist practice; AAD guidelines list cephalexin as second-line.

Level of evidence quality: Weak — no paediatric RCTs. Expert consensus.

Specialist only: Dermatologist guidance recommended.

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing frequency context: Cephalexin is typically dosed two to four times daily (q12h BD, q8h TDS, or q6h QDS) depending on the indication and severity. Because cephalexin has a short half-life (~1 hour) and time-dependent killing, consistent dosing intervals are important — but the wide therapeutic index provides some forgiveness for minor delays.

Structured by dosing frequency:

Twice-daily (BD / q12h) dosing (e.g., GAS pharyngitis 500 mg q12h):

Scenario	Action
Missed dose remembered within 6 hours	Take the missed dose immediately. Resume next dose at the regular scheduled time.
Missed dose remembered >6 hours late (i.e., close to next dose)	Skip the missed dose entirely. Take the next dose at the regular time. Do NOT double up.

Three-times-daily (TDS / q8h) dosing (most common paediatric and adult regimen):

Scenario	Action
Missed dose remembered within 3–4 hours	Take the missed dose immediately. Resume regular schedule.
Missed dose remembered >4 hours late (close to next dose)	Skip the missed dose. Take the next dose at the regular time. Do NOT double up.

Four-times-daily (QDS / q6h) dosing (serious infections, osteomyelitis step-down):

Scenario	Action
Missed dose remembered within 2 hours	Take the missed dose immediately. Resume regular schedule.
Missed dose remembered >2 hours late (close to next dose)	Skip the missed dose. Take the next dose at regular time. Do NOT double up.

Once-daily dosing (UTI prophylaxis — 125–250 mg at bedtime):

Scenario	Action
Missed bedtime dose remembered the same night / early next morning	Take the missed dose as soon as remembered (even if it’s 3–4 AM). Resume regular bedtime dosing the next night.
Missed dose remembered the next day (>12 hours late)	Skip the missed dose. Take the next dose at the regular bedtime. Do NOT double up.

Single-dose (IE prophylaxis — 2 g before dental procedure):

Scenario	Action
Forgot to take before the procedure	If remembered before or during the procedure → take immediately (even if <30 minutes before). AHA guidelines state the dose can be taken up to 2 hours after the procedure if missed beforehand.
Remembered more than 2 hours after the procedure	Contact the prescribing physician. The benefit of post-procedural dosing >2 hours after is uncertain.

Additional guidance:

ℹ️ Cephalexin does NOT require steady-state levels for efficacy (unlike antidepressants or antiepileptics). Each dose achieves therapeutic levels independently. A single missed dose, while not ideal, is unlikely to cause treatment failure for most infections — the concern is cumulative missed doses reducing the total time above MIC.

What to tell patients/caregivers (simple language):
“If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next one on time. Never take two doses at once. Try to space your doses evenly through the day.”

Prolonged non-adherence / drug holiday guidance:

Situation	Guidance
1 day of missed doses during a standard SSTI or UTI course	Resume at regular dose and schedule. Extend the total course by 1 day.
2+ consecutive days missed	Resume at regular dose. Contact treating physician — may need to extend course or reassess clinical response. No re-titration needed (cephalexin has no titration requirement).
Missed doses during GAS pharyngitis treatment	⚠️ Complete the full 10-day course from the first dose to the last — do NOT count missed days as “treatment days.” If more than 2 days missed, contact the physician; the course may need to be restarted from day 1 to ensure GAS eradication for ARF prevention.
Missed doses during osteomyelitis oral step-down	⚠️ Contact treating physician. Missed doses during treatment of serious infections risk subtherapeutic levels and treatment failure. May need to reassess clinically and consider extending the course or returning to IV therapy.
Missed doses during UTI prophylaxis	Resume at next scheduled bedtime dose. A few missed prophylactic doses do NOT require course restart. However, recurrent missed doses may increase breakthrough UTI risk — reassess adherence and address barriers.

Rebound effects on discontinuation: Not applicable — cephalexin does not cause rebound effects or withdrawal syndrome. It can be stopped without tapering at the end of the prescribed course.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

ORAL FORMULATIONS — ADMINISTRATION NOTES

Capsules (250 mg, 500 mg):

Topic	Details
Swallow whole	Swallow intact with a full glass of water (at least 100–150 mL).
Can be taken with or without food	✔ Food does NOT significantly affect absorption. Taking with food may reduce GI upset (nausea, stomach discomfort).
Crush / split allowed?	Capsules are NOT designed to be crushed or split. However, the capsule can be opened and contents mixed with a small amount of soft food (jam, yogurt, honey for children >1 year) and consumed immediately. This is an off-label administration method but widely practised and acceptable — absorption is not significantly affected.
Enteral tube compatible?	Not ideal for capsule form. Use oral suspension or dispersible tablets for NG/PEG tube administration. If capsules are the only available formulation → open capsule, disperse contents in 15–20 mL water, administer via tube, and flush with 15–20 mL water before and after. The powder does not dissolve fully — some grittiness expected.

Tablets (250 mg, 500 mg, 1 g):

Topic	Details
Swallow whole	Film-coated tablets — swallow intact with water.
Crush / split	Standard film-coated tablets may be split (scored tablets) or crushed if needed. Dispersible tablets should be dissolved in water.
Enteral tube	Dispersible tablets: dissolve in 15–20 mL water → administer via tube → flush with water. Film-coated tablets: crush to fine powder, disperse in water, administer via tube.

Dry Syrup / Oral Suspension (125 mg/5 mL, 250 mg/5 mL):

ℹ️ This is the critical paediatric formulation. Proper reconstitution and storage are essential.

Parameter	Details
Reconstitution	Add the specified volume of freshly boiled and cooled water (amount stated on bottle label — typically 60–70 mL for a standard bottle; varies by manufacturer). Add water in two portions: add half, shake vigorously for 30 seconds, add remaining water, shake again until a uniform suspension is formed.
Final concentration	125 mg/5 mL (25 mg/mL) or 250 mg/5 mL (50 mg/mL) — verify with specific manufacturer label.
Shake well before each use	⚠️ CRITICAL. The drug settles to the bottom upon standing. Failure to shake results in inconsistent dosing — initial doses may be subtherapeutic (mostly vehicle), and later doses may be supratherapeutic (concentrated drug). Shake the bottle vigorously for 10–15 seconds before every use.
Measure dose accurately	Use the provided measuring cup, calibrated oral syringe, or dropper. ⛔ Do NOT use household teaspoons/tablespoons — they are inaccurate by ±20–50%. A calibrated oral syringe (5 mL or 10 mL) is the most accurate method for paediatric dosing.
Timing relative to food	Can be given before, during, or after meals. Giving with food may reduce GI upset and improve palatability (child is eating → less focus on medicine taste).
Enteral tube	Shake well. Draw up measured dose with oral syringe. Flush NG/PEG tube with 5–10 mL water before and after administration. Suspension may clog narrow-bore tubes → flush thoroughly.

Storage After Reconstitution:

Condition	Shelf Life	Notes
Refrigerated (2–8°C)	14 days (most manufacturers state 14 days — verify with specific product label; some state 7 days)	✔ PREFERRED storage method. Refrigeration maintains potency and improves palatability (cold suspension tastes better to children).
Room temperature (25°C)	7 days (most manufacturers; some allow up to 14 days at 25°C — verify label)	Acceptable when refrigeration is unavailable.

⚠️ Indian hot-climate storage note: In Indian summer conditions (ambient temperature frequently >35–40°C), reconstituted cephalexin suspension stored at room temperature degrades faster than the labelled stability at 25°C.

✔ Best practice: Store reconstituted suspension in the refrigerator. If the family has a refrigerator, this is the standard advice.
⚠️ If no refrigerator is available (common in rural India and urban slum populations):
- Store in the coolest part of the house (away from kitchen, direct sunlight, and heat sources)
- Wrap the bottle in a damp cloth (evaporative cooling)
- Use within 5–7 days rather than the label-stated 14 days
- Consider prescribing the capsule formulation instead (if the child can swallow capsules, or if capsules can be opened and contents mixed with food) — dry capsules are stable at room temperature and are not temperature-sensitive

Before reconstitution: Store dry powder bottles at room temperature (below 30°C), in a cool, dry place, protected from moisture. The dry powder is stable and does NOT require refrigeration.

Paediatric Drops (125 mg/1.25 mL = 100 mg/mL):

Parameter	Details
Ready to use	Pre-reconstituted dropper formulation (no reconstitution needed) — OR dry powder requiring reconstitution (varies by manufacturer — check label).
Administration	Use the calibrated dropper provided. Draw up the prescribed volume. Administer directly into the infant’s mouth (towards the inner cheek, not directly into the throat — to prevent choking). May be mixed with a small amount of breast milk, formula, or water in a spoon and given immediately.
Storage	Same as oral suspension — refrigerate after opening. Use within the stated period (typically 7–14 days).

RECONSTITUTION — INJECTABLE FORMULATIONS

⛔ NOT APPLICABLE. Cephalexin is an oral-only drug. There is no parenteral (IV/IM) formulation. No reconstitution for injection is required.

For parenteral first-generation cephalosporin therapy, use cefazolin (IV/IM) — see cefazolin monograph (separate entry).

SPECIAL ADMINISTRATION NOTES

Topic	Details
Filter requirements	Not applicable (oral drug).
Flush line	Not applicable for IV (oral only). For NG/PEG tube: flush with 5–15 mL water before and after.
Extravasation	Not applicable (oral drug).
IM injection	Not applicable (no parenteral formulation).
Interaction with antacids	No significant interaction with antacids or H2 blockers. Cephalexin absorption is NOT affected by gastric pH to a clinically meaningful degree. Can be co-administered with antacids (aluminium/magnesium hydroxide), ranitidine, or PPIs without timing separation.
Interaction with dairy / calcium	✔ No interaction. Unlike tetracyclines and fluoroquinolones, cephalexin does NOT chelate with calcium. It can be taken with milk, dairy products, and calcium supplements without any reduction in absorption. This is a useful practical point for paediatric counselling (milk is a major component of children’s diets).
Interaction with iron supplements	✔ No significant interaction. Cephalexin does not chelate with iron. Can be co-administered with iron supplements.
Alcohol	No absolute contraindication to alcohol (cephalexin does NOT cause a disulfiram-like reaction — unlike some other cephalosporins such as cefoperazone). However, alcohol may worsen GI side effects (nausea) and is generally not recommended during active infection.

COLD-CHAIN DRUG GUIDANCE

Cephalexin is NOT a cold-chain drug in any formulation (dry powder, capsules, tablets).

Formulation	Storage Before Use	After Reconstitution / Opening
Capsules / Tablets	Room temperature (below 30°C). Protect from moisture and direct sunlight. Store in original blister/container.	Not applicable (stable as dispensed).
Dry syrup (before reconstitution)	Room temperature (below 30°C). Protect from moisture.	After reconstitution: Refrigerate (2–8°C) — preferred. Room temperature acceptable for 7 days (less in extreme heat — see notes above). Use within 14 days (refrigerated) or 7 days (room temp).
Paediatric drops	Per manufacturer instructions (usually room temperature before opening).	After opening: Refrigerate. Use within stated period (7–14 days).

⚠️ Indian practical storage advice:

✔ Capsules and dry powder (before reconstitution) are stable at Indian room temperature (<30°C) and do NOT require cold storage
⚠️ During extreme summer (>40°C in many Indian cities), store capsules in the coolest room, away from the kitchen and windows. Use a cotton or cloth pouch to protect from humidity (especially in coastal/humid areas)
⚠️ Reconstituted suspension MUST be refrigerated if possible. If no refrigerator → use within 5–7 days and store in the coolest available location
⚠️ Do NOT freeze any formulation of cephalexin — freezing damages the suspension formulation irreversibly

RENAL ADJUSTMENT

eGFR formula specification: Dosing adjustments below are based on Cockcroft-Gault estimated creatinine clearance (CrCl), as original pharmacokinetic data for cephalexin used this method. CKD-EPI eGFR may overestimate renal function in elderly and cachectic patients compared to Cockcroft-Gault CrCl. For cephalexin, this distinction is clinically important because ~80–95% of the drug is excreted unchanged renally — making renal function the dominant determinant of drug clearance. Use Cockcroft-Gault CrCl for dosing decisions whenever possible. If only CKD-EPI eGFR is available, it is an acceptable surrogate for most patients, with the caveat above.

General principle: Cephalexin has a wide therapeutic index and is generally well-tolerated even at high doses. Significant dose adjustment is NOT required until renal impairment is moderate-to-severe. The primary adjustment strategy is extending the dosing interval rather than reducing the individual dose — this maintains adequate peak concentrations (relevant for time-dependent killing) while preventing drug accumulation.

ℹ️ Key PK reminder: Cephalexin’s half-life is ~1 hour in normal renal function but prolongs to 5–6 hours at CrCl <10 mL/min and up to 20–40 hours in anuria. At these extremes, significant accumulation occurs with standard dosing. However, cephalexin has a wide therapeutic index — toxicity from modest accumulation is rare and primarily manifests as GI intolerance, rarely as neurotoxicity (seizures) at very high accumulated levels.

Standardised Renal Adjustment Table:

CrCl (mL/min)	Dose Adjustment	Frequency	Max Daily Dose	Notes
>60	No adjustment required. Standard dosing.	q6–8h per indication	Per indication (up to 4 g/day for osteomyelitis)	No changes needed. Full dose, full frequency.
30–60	No dose adjustment required for standard-dose therapy (250–500 mg q8h). For high-dose therapy (1 g q6h for osteomyelitis), consider extending interval to q8h.	Standard q8h; high-dose q8h instead of q6h	Standard per indication; high-dose: max 3 g/day	Half-life modestly prolonged (~1.5–2 h). Monitor renal function weekly if on prolonged course.
15–30	Recommended: Standard per-dose amount, but extend interval to q8–12h.	q8–12h	Mild-moderate infections: max 1.5 g/day. Serious infections: max 2 g/day.	⚠️ Half-life prolonged to ~2–4 h. Some accumulation expected. Monitor for GI side effects. For UTI treatment at this GFR: cephalexin still achieves adequate urinary concentrations due to tubular secretion (even though GFR is reduced, OAT-mediated secretion persists partially).
<15 (non-dialysis)	Recommended: Reduce dose AND extend interval. Use 250 mg q12h for mild infections; 250–500 mg q12h for moderate-severe infections.	q12h	Max 1 g/day	⚠️ Half-life prolonged to ~5–6 hours (up to 20–40 h in anuria). Significant accumulation with standard dosing. Monitor for neurological symptoms (confusion, myoclonus — rare) at very high accumulated levels.
Haemodialysis	Cephalexin is moderately dialysable (~30–40% removed in a standard 4-hour HD session due to low protein binding and moderate Vd). Supplemental dose required post-HD. Base dosing: 250–500 mg q12–24h (depending on infection severity). Post-HD supplement: give an additional 250–500 mg after each haemodialysis session.	q12–24h + post-HD supplement	Individualise based on infection severity	Time one of the regular doses to be given BEFORE the HD session. Then give the supplemental dose AFTER HD. On non-dialysis days, continue the regular q12–24h schedule.
Peritoneal dialysis (CAPD/APD)	Poorly removed by peritoneal dialysis (~10–15%). Use the <15 mL/min dosing (250–500 mg q12h). No supplemental dose after PD exchanges.	q12h	Max 1 g/day	Monitor clinically and by renal function.
CRRT	Data very limited for cephalexin during CRRT (cephalexin is oral-only and rarely the drug of choice in ICU patients requiring CRRT — parenteral cefazolin or broader agents are preferred). If oral cephalexin must be used during CRRT (step-down in a recovering CRRT patient): use 250–500 mg q8–12h and monitor clinically.	q8–12h	Individualise	CRRT provides continuous but modest clearance. Use clinical judgment. If TDM is available (very rarely for cephalexin): target free trough >MIC.

Augmented Renal Clearance (ARC):

ℹ️ ARC is defined as CrCl >130 mL/min (measured). Cephalexin is almost exclusively an outpatient oral drug and is rarely used in the ICU population where ARC is most relevant (parenteral agents are preferred in ICU). Therefore, ARC is generally NOT a major dosing concern for cephalexin in clinical practice.

However, in the uncommon scenario of a recovering young ICU patient with ARC who is being transitioned to oral cephalexin for step-down:

Use the higher end of dosing (500 mg–1 g q6h)
Consider extended infusion of IV cefazolin instead if adequate oral levels are uncertain
ARC is transient — standard dosing can be resumed as the hyperdynamic state resolves

ℹ️ Source: General pharmacokinetic principles. No specific Indian guideline addresses ARC for cephalexin.

HEPATIC ADJUSTMENT

General principle: Cephalexin undergoes virtually no hepatic metabolism. It is excreted unchanged by the kidneys (~80–95%). Therefore:

✔ No hepatic dose adjustment is required — at any degree of hepatic impairment (Child-Pugh A, B, or C)
✔ Hepatic failure, cirrhosis, and hepatocellular disease do NOT alter cephalexin clearance
✔ No active metabolites exist — no risk of metabolite accumulation in liver disease
✔ Protein binding is very low (~10–15%) — hypoalbuminaemia in cirrhosis does NOT meaningfully alter free drug levels (already ~85–90% free in normal albumin)
✔ Cephalexin has very low intrinsic hepatotoxicity — it is one of the safest antibiotics from a hepatic perspective

Child-Pugh-Based Guidance:

Hepatic Impairment	Dose Adjustment
Mild (Child-Pugh A)	No adjustment required.
Moderate (Child-Pugh B)	No adjustment required.
Severe (Child-Pugh C)	No adjustment required. ℹ️ However, patients with decompensated cirrhosis often have concurrent hepatorenal syndrome (HRS) or reduced renal function → dose-adjust for the renal function component per the Renal Adjustment table above.

Concurrent hepatotoxin note:

ℹ️ Cephalexin has negligible intrinsic hepatotoxicity. It does not cause clinically significant drug-induced liver injury (DILI). Unlike flucloxacillin (HLA-B*57:01-associated cholestatic hepatitis) or amoxicillin-clavulanate (clavulanate-associated cholestatic DILI), cephalexin has an excellent hepatic safety profile.

Rifampicin co-administration: No pharmacokinetic interaction (cephalexin is not a CYP substrate). No additive hepatotoxicity concern. No dose adjustment needed.
Isoniazid / Pyrazinamide co-administration: No pharmacokinetic interaction. No additive hepatotoxicity concern. Can be co-prescribed safely.
Methotrexate co-administration: See Drug Interactions — renal tubular secretion competition (OAT-mediated) is the concern, NOT hepatotoxicity.
Valproate co-administration: No interaction.
Antiretrovirals: No hepatic interaction. No concern for additive hepatotoxicity.

💡 Clinical pearl: Cephalexin is one of the safest antibiotics to use in patients with liver disease — no hepatic dose adjustment, no hepatotoxicity risk, no CYP interactions. This makes it a good choice for MSSA/streptococcal SSTI or UTI in patients with cirrhosis or chronic liver disease.

CONTRAINDICATIONS

⛔ Absolute contraindications — Cephalexin must NEVER be used in these situations:

Contraindication	Clinical Rationale
⛔ History of anaphylaxis or severe immediate (type I) hypersensitivity to cephalexin or ANY cephalosporin	Risk of fatal anaphylaxis on re-exposure. Prior anaphylaxis to any cephalosporin (urticaria + angioedema + bronchospasm + hypotension within 1 hour of administration) is an absolute bar to ALL cephalosporins.
⛔ History of severe delayed hypersensitivity to cephalosporins (SJS/TEN, DRESS syndrome, acute interstitial nephritis, haemolytic anaemia attributed to cephalosporins)	Risk of recurrence of severe immune-mediated reaction. These are often T-cell-mediated and may recur with any cephalosporin, though cross-reactivity between different cephalosporins is variable.
⛔ History of anaphylaxis to PENICILLINS — ONLY if the anaphylaxis was severe (cardiovascular collapse/intubation) AND the prescriber cannot provide observed graded challenge/supervised first-dose administration	See detailed cross-reactivity guidance below. ℹ️ This is a nuanced contraindication — current evidence suggests the actual penicillin-cephalosporin cross-reactivity rate is ~1–2% (not the historically cited 10%). Many patients with penicillin anaphylaxis CAN safely receive cephalosporins under supervised conditions. See Cautions for graded approach.

Allergy cross-reactivity guidance — Detailed:

This is a critically important clinical topic for cephalexin prescribing, as penicillin allergy is extremely commonly reported in India (often inaccurately).

Related Drug/Class	Cross-Reactivity Risk with Cephalexin	Guidance
Other cephalosporins (all generations)	Variable — depends on R1 side-chain similarity. First-generation cephalosporins (cefazolin, cefadroxil, cephradine) share similar side chains with cephalexin → higher cross-reactivity within this group. Third/fourth-generation cephalosporins (ceftriaxone, cefepime) have very different side chains → lower cross-reactivity with cephalexin. Overall: if the patient had a confirmed allergic reaction to a specific cephalosporin, the safest approach is to use a cephalosporin with a different R1 side chain under observation. If the reaction was anaphylaxis to ANY cephalosporin → avoid ALL cephalosporins.	If allergic to cefazolin or cefadroxil (same generation, similar side chains) → avoid cephalexin. If allergic to ceftriaxone or cefepime (different side chains) → cephalexin may be used with first-dose observation (specialist decision).
Penicillins (amoxicillin, ampicillin, cloxacillin, piperacillin, etc.)	Low overall: ~1–2% (modern data strongly disputes the historically cited 10% cross-reactivity figure, which was based on early contaminated preparations). Cross-reactivity is primarily mediated by shared R1 side chains, NOT by the shared beta-lactam ring. Cephalexin and ampicillin/amoxicillin share a similar R1 aminobenzyl side chain → slightly higher cross-reactivity (~2–3%) between cephalexin and amoxicillin specifically. Cephalexin and cloxacillin/flucloxacillin have very different side chains → cross-reactivity is very low (~0.5–1%).	(a) Penicillin allergy — NON-anaphylactic (mild rash, GI upset, vague history): ✔ Cephalexin can be used safely. First dose under observation (30–60 min) is prudent but not always mandatory. Risk is very low (~1%). (b) Penicillin allergy — confirmed ANAPHYLAXIS: ⚠️ Risk is still low (~1–2%), but the consequence of recurrence is severe. Options: (i) Perform penicillin skin testing (available at select Indian tertiary centres — if negative, cephalosporin use is safe); (ii) Administer cephalexin under observed graded challenge (specialist supervision, resuscitation equipment available — give 1/10th dose → observe 30 min → full dose → observe 1 hour); (iii) If skin testing and graded challenge are not feasible and the clinical need is not urgent → use a non-beta-lactam alternative (TMP-SMX, clindamycin, doxycycline — depending on indication).
Carbapenems (meropenem, imipenem, ertapenem)	Very low (<1%) cross-reactivity with cephalosporins.	Carbapenems can generally be used safely in cephalosporin-allergic patients, including those with anaphylaxis. Administer first dose under observation.
Monobactams (aztreonam)	Negligible cross-reactivity with cephalosporins (different ring structure). EXCEPTION: aztreonam shares a side chain with ceftazidime → cross-reactivity exists between aztreonam and ceftazidime specifically. No shared side chain with cephalexin → safe to use.	Aztreonam is safe in cephalexin-allergic patients. Limited availability in India.

ℹ️ Penicillin allergy de-labelling — important stewardship note for Indian practice:
True penicillin allergy is vastly over-reported in India. Many patients labelled “allergic” to penicillin have had:

Non-allergic GI side effects (nausea, diarrhoea)
Non-specific childhood rash (may have been viral exanthem coinciding with antibiotic use)
Family history of allergy (not personal)
Vague/undocumented history

Impact of false penicillin allergy labels:

Inappropriate avoidance of beta-lactams (the safest, most effective, and cheapest antibiotic class)
Use of broader-spectrum or more expensive alternatives (fluoroquinolones, macrolides, carbapenems) → increased AMR
Denial of optimal therapy (e.g., penicillin for syphilis, amoxicillin for GAS pharyngitis)

💡 De-labelling recommendation: When a patient reports “penicillin allergy,” take a careful structured history:

What happened? (Describe exact symptoms)
How soon after taking the medicine? (Minutes = possible IgE-mediated; days = delayed)
Did it require emergency treatment? (Adrenaline, hospitalisation?)
How long ago?
Has the patient ever taken any other penicillin or cephalosporin since then without a reaction?

If the history is vague, non-specific, or inconsistent with true allergy → the patient likely does NOT have a genuine penicillin allergy → cephalexin and other beta-lactams are likely safe. Consider skin testing or oral challenge (specialist setting) for definitive de-labelling.

CAUTIONS

⚠️ High-priority cautions:

Caution	Clinical Concern	Monitoring Required
⚠️ History of non-severe penicillin allergy (minor rash, GI intolerance, vague/remote history)	Low (~1–2%) but non-zero risk of cross-reactive allergic reaction. For a drug as commonly prescribed as cephalexin, even a 1% rate translates to a meaningful absolute number of reactions across the population.	Administer first dose under observation (30–60 minutes) in a clinical setting where adrenaline and resuscitation equipment are available. If no reaction to first dose → subsequent doses can be taken at home without observation.
⚠️ Renal impairment (eGFR <30 mL/min)	Drug accumulation due to reduced renal clearance. Half-life prolonged from ~1 h to ~5–6 h (or longer in anuria). Risk of elevated serum levels → GI toxicity, rarely neurotoxicity (seizures at very high levels).	Extend dosing interval per Renal Adjustment table. Monitor renal function every 1–2 weeks if on prolonged course. Monitor for excessive GI symptoms or neurological signs.
⚠️ Prolonged high-dose therapy (>2 weeks, especially at 4 g/day for osteomyelitis)	Increased risk of: GI intolerance (dose-dependent diarrhoea), superinfection (oral/vaginal candidiasis, CDI), and rarely haematological effects (neutropenia — very rare with cephalexin).	CBC every 2 weeks during prolonged courses. Monitor for CDI (severe diarrhoea, fever, abdominal cramps). Renal function checks if high-dose.
⚠️ Concurrent methotrexate therapy	Cephalexin may reduce renal tubular secretion of methotrexate (competition at OAT transporters) → increased methotrexate levels → potential toxicity (mucositis, pancytopenia, hepatotoxicity, renal toxicity).	See Major Drug Interactions. Monitor methotrexate levels and CBC if co-prescribed.

Standard cautions:

Caution	Notes
History of GI disease / antibiotic-associated colitis	All antibiotics, including cephalexin, can cause Clostridioides difficile infection (CDI). Risk with cephalexin is lower than with fluoroquinolones, clindamycin, or broad-spectrum cephalosporins — but still present. Monitor for severe diarrhoea. If severe/bloody diarrhoea → stop cephalexin, test for CDI.
Concomitant probenecid	Probenecid blocks renal tubular secretion of cephalexin → increased serum levels and prolonged half-life (~30–50% increase in AUC). This is occasionally used intentionally to boost levels (FDC available — see Part 1). No dose reduction needed at standard cephalexin doses if probenecid is co-prescribed for gout, but monitor for GI side effects.
Diabetes mellitus — urine glucose testing	Cephalexin may cause false-positive urine glucose with copper-reduction methods (Benedict’s test, Clinitest). Glucose oxidase methods (standard dipsticks) are NOT affected. Clinically relevant in diabetic patients monitoring urine glucose (uncommon in current practice — blood glucose monitoring is standard).
Superinfection risk	Prolonged cephalexin use (especially >10 days) may cause overgrowth of non-susceptible organisms: Candida (oral thrush, vaginal candidiasis), resistant Gram-negatives (ESBL-producers, Pseudomonas), Enterococcus, and CDI. Monitor for new symptoms and treat superinfections promptly.
Seizure history / CNS disease	At standard therapeutic doses with normal renal function, neurotoxicity risk is negligible. Risk is theoretical only at very high doses with concurrent severe renal impairment (drug accumulation). No dose adjustment for seizure history alone — just ensure renal-appropriate dosing.
Laboratory test interference — Coombs test	Cephalexin may cause a false-positive direct antiglobulin test (DAT / direct Coombs test) — relevant for cross-matching blood. This does NOT indicate haemolytic anaemia — it is an in-vitro artifact. Inform the blood bank if the patient is on cephalexin and requires cross-matching. Clinically significant autoimmune haemolytic anaemia from cephalexin is extremely rare.
Oral contraceptive efficacy	Evidence does NOT support a clinically significant reduction in OCP efficacy with cephalexin (or any cephalosporin). However, for medicolegal prudence in India, some practitioners advise additional barrier contraception during antibiotic courses. The evidence basis for this advice is very weak.

PREGNANCY

Parameter	Details
Overall safety statement	Cephalexin is considered SAFE in pregnancy — widely used for treatment of maternal infections across all trimesters. Classified in former US-FDA Pregnancy Category B (animal studies showed no fetal harm; no adequate controlled human studies — but extensive clinical use spanning decades supports safety). One of the most commonly prescribed antibiotics in pregnancy worldwide and in India.
Teratogenicity	No known teratogenic risk. Cephalosporins as a class have no documented teratogenic effect at any gestational age based on decades of clinical experience and multiple observational studies. No specific developmental window of concern. Large registry studies (including the Hungarian Case-Control Surveillance of Congenital Abnormalities) have not identified any association between cephalexin use and birth defects.
First trimester	No evidence of teratogenicity. May be used when clinically indicated.
Second trimester	No specific additional risks. May be used when clinically indicated.
Third trimester	No specific additional risks. Cephalexin crosses the placenta (fetal serum levels approximately 25–50% of maternal levels). No documented fetal or neonatal toxicity from maternal cephalexin use.
PK changes in pregnancy	Increased Vd (~40–50% plasma volume expansion) and increased GFR (~50%) → lower cephalexin serum levels at standard doses. However, since cephalexin achieves very high urinary concentrations (the most common pregnancy indication is UTI), efficacy for UTI is generally preserved. For non-UTI infections in pregnancy, use the higher end of the dose range (500 mg q6–8h).
Common indications in Indian obstetric practice	(1) UTI / Asymptomatic bacteriuria (ASB) — second-line after nitrofurantoin (nitrofurantoin contraindicated near term and in G6PD deficiency). (2) SSTI — pyoderma, infected episiotomy, post-LSCS wound infection. (3) GBS prophylaxis alternative — for women with non-anaphylactic penicillin allergy who are GBS-positive (cephalexin is NOT recommended for intrapartum GBS prophylaxis — IV cefazolin is the alternative to penicillin G for intrapartum use; cephalexin may be used for antepartum GBS UTI treatment).
Preferred alternatives in Indian obstetric practice	For UTI: nitrofurantoin (first-line in first/second trimester if susceptible; avoid in third trimester near term), amoxicillin (if susceptible), amoxicillin-clavulanate, fosfomycin (single-dose — limited availability in India). Cephalexin IS one of the preferred agents — not a last resort.
What to monitor	Standard infection monitoring (temperature, clinical response). No specific fetal monitoring required solely due to cephalexin use. Standard antenatal care.
Pre-conception counselling	Not required — cephalexin is an acute-use antibiotic, not a chronic medication. No washout period needed before conception.
Contraception requirement	Not required — no teratogenic potential.

Pregnancy Prevention Programme / Registry: Not applicable. Cephalexin does not have a mandatory pregnancy prevention programme or exposure registry.

Fertility Effects:

No known effect on male or female fertility. Cephalexin does not affect spermatogenesis, ovulation, or reproductive hormones based on available data.

LACTATION

Parameter	Details
Compatible with breastfeeding?	Yes — fully compatible with breastfeeding. Cephalexin is one of the safest antibiotics during lactation. It is widely used for lactational mastitis (MSSA — the most common cause) — making it especially relevant that it is safe to continue breastfeeding during treatment.
Drug levels in breast milk	Low. Cephalexin is excreted in breast milk in low concentrations (peak milk levels ~0.2–1.5 mcg/mL after a 500 mg oral dose — this is very low relative to the infant’s therapeutic dose range). Estimated relative infant dose (RID): <1–2% of the weight-adjusted maternal dose — well below the generally accepted safety threshold of 10%. The low protein binding (~10–15%) allows some transfer into milk, but the absolute amounts are clinically negligible.
What to monitor in infant	Monitor for: (a) Diarrhoea — most common; usually mild and self-limiting; due to alteration of infant gut flora by trace drug levels. (b) Oral thrush / candidal nappy rash — from gut flora alteration. © Allergic reaction — extremely rare. (d) Feeding difficulties — very rarely reported. ℹ️ In practice, adverse effects in breastfed infants from maternal cephalexin are very uncommon and almost always mild.
Timing advice	Not necessary for safety — drug levels in milk are very low regardless of dose timing. If the mother wishes to minimise exposure, she can take the dose immediately after completing a breastfeed — but this is NOT required and should not be a barrier to timely dosing.
Preferred alternatives	Cephalexin IS one of the preferred antibiotics during lactation. If an alternative is needed: amoxicillin (safe), amoxicillin-clavulanate (safe), cloxacillin (safe).
Lactational mastitis note	ℹ️ Cephalexin 500 mg q6–8h is a first-line treatment for infective lactational mastitis (MSSA). Continued breastfeeding (or expressing) from the affected breast is strongly encouraged — it aids resolution and the drug in milk does not harm the infant.

Effect on milk production:

No known effect on milk production. Cephalexin does not suppress or enhance lactation. No galactorrhoea reported.

Temporary incompatibility guidance:

Not applicable — cephalexin is fully compatible with breastfeeding throughout the treatment course. No “pump and discard” is required.

ELDERLY

Definition: For this formulary, elderly is defined as ≥60 years, consistent with Indian Census and NPHCE definitions.

General principle: Cephalexin is well-tolerated in elderly patients. The primary consideration is renal function — age-related decline in GFR is the main determinant of dose adjustment. There are no specific age-related pharmacodynamic concerns (no CNS depression, no postural hypotension, no anticholinergic effects).

Parameter	Guidance
Recommended starting dose	Same as adult dose for the indication — provided renal function is adequate (eGFR >60). For elderly with eGFR 30–60: standard dosing is usually fine (no adjustment needed at this level). For eGFR <30: adjust per Renal Adjustment table.
Need for slower titration	Not applicable — cephalexin is not titrated.
Renal function consideration	⚠️ Always estimate eGFR/CrCl before prescribing in elderly. A serum creatinine that appears “normal” (e.g., 1.0 mg/dL) in an elderly patient with reduced muscle mass may correspond to CrCl <40 mL/min. Use the Cockcroft-Gault formula (which accounts for age, weight, and sex) or CKD-EPI eGFR. If eGFR <30 → extend dosing interval per Renal Adjustment table.
Falls risk	Minimal. Cephalexin does NOT cause dizziness, drowsiness, postural hypotension, or sedation. It is NOT a falls risk drug.
Confusion / Delirium	Not a typical effect at standard therapeutic doses with appropriate renal dosing. Neurotoxicity (confusion, myoclonus) is theoretical only at very high accumulated doses in anuria — prevented by appropriate renal dose adjustment. The underlying infection is a far more common cause of delirium in elderly.
GI tolerability	Elderly patients may experience more GI upset (nausea, diarrhoea) than younger adults. Taking cephalexin with food reduces GI symptoms. Ensure adequate hydration. Monitor for CDI — elderly are at higher CDI risk (especially those hospitalised, on PPIs, or with prior antibiotic exposure).
Polypharmacy interactions	Cephalexin has very few drug interactions (no CYP metabolism, minimal transporter interactions). This makes it one of the safest antibiotics in the polypharmacy context that is universal in elderly Indian patients. Key interaction to check: methotrexate (if on low-dose MTX for RA).
QT prolongation	Cephalexin does NOT prolong the QT interval.
Beers Criteria / STOPP-START	Cephalexin is NOT listed on the Beers Criteria or STOPP-START lists as a potentially inappropriate medication in the elderly. It is considered a safe drug for elderly patients.
Common clinical scenarios in elderly Indian patients	(a) UTI in elderly diabetic woman → cephalexin is appropriate for uncomplicated cystitis if culture shows susceptibility. Always obtain urine culture in elderly. Consider nitrofurantoin first-line if eGFR >30. (b) SSTI in elderly diabetic → cephalexin is appropriate for mild-moderate MSSA SSTI. For diabetic foot infection → broader coverage needed (not cephalexin monotherapy). © Post-operative wound infection (e.g., after knee/hip replacement) → cephalexin as oral step-down from IV cefazolin is excellent. (d) Elderly on warfarin → cephalexin does NOT significantly interact with warfarin (no CYP interaction). Minor theoretical effect via gut flora alteration — monitor INR if prolonged course, but interaction is clinically insignificant in most cases.

Anticholinergic burden:

No anticholinergic burden. Cephalexin has no anticholinergic properties. Anticholinergic Cognitive Burden (ACB) score = 0. No concern for cumulative anticholinergic burden in elderly polypharmacy.

Deprescribing guidance:

Deprescribing: Not applicable. Cephalexin is an acute-use antibiotic given for defined durations. It is not subject to deprescribing. Once the treatment course is completed, the drug is simply stopped (no taper required, no withdrawal effects).

ℹ️ Exception: If cephalexin is being used for long-term UTI prophylaxis or chronic suppressive therapy for prosthetic joint infection — periodic reassessment of continued need is appropriate. UTI prophylaxis should be reviewed every 6–12 months. Suppressive bone/joint therapy should be reviewed by the orthopaedic surgeon and ID specialist periodically.

MAJOR DRUG INTERACTIONS

ℹ️ Cephalexin has remarkably few drug interactions — this is one of its major clinical advantages. It is not metabolised by CYP450 enzymes, not a CYP inhibitor or inducer, not a significant P-glycoprotein substrate, and has minimal transporter interactions beyond OAT1/OAT3 (renal tubular secretion). The interactions listed below are the only ones of clinical significance.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Methotrexate	Cephalexin may compete with methotrexate for renal tubular secretion via OAT1/OAT3 transporters → reduced methotrexate clearance → increased methotrexate serum levels → potential toxicity. Additionally, cephalexin may reduce renal blood flow marginally at very high doses, further reducing MTX clearance.	⚠️ Risk of methotrexate toxicity: mucositis, pancytopenia, hepatotoxicity, renal toxicity. Risk is highest with high-dose methotrexate (oncology doses — grams per m²). With low-dose weekly methotrexate (RA/psoriasis — 7.5–25 mg/week), the risk is lower but still clinically relevant in patients with borderline renal function.	Acute onset: Manifests within days, especially during high-dose MTX cycles (24–72 hours). For low-dose weekly MTX: may take 1–2 weeks for clinically significant MTX accumulation.	⚠️ For high-dose MTX (oncology): Avoid co-prescription if possible. If cephalexin is essential → monitor MTX levels closely, ensure adequate hydration and urinary alkalinisation, have leucovorin rescue available. Oncology team must be informed. For low-dose weekly MTX (RA/psoriasis): Co-prescription is usually tolerable for short cephalexin courses (5–7 days). Monitor CBC and renal function at 1 week. Avoid concurrent use for prolonged cephalexin courses (>7 days) if possible. If not avoidable → monitor CBC, renal function, and LFT weekly during combined therapy.
Aminoglycosides (gentamicin, amikacin)	Additive nephrotoxicity — cephalexin alone has very low nephrotoxicity, but concurrent aminoglycosides (which are inherently nephrotoxic) may have slightly increased nephrotoxic risk when combined with any cephalosporin. The mechanism is additive renal tubular damage. Additionally, in-vitro studies show cephalosporins may potentiate aminoglycoside nephrotoxicity in animal models.	⚠️ Increased risk of nephrotoxicity — primarily driven by the aminoglycoside. The cephalexin contribution is modest but additive.	Gradual onset: Nephrotoxicity manifests over days of combined therapy.	Monitor renal function (serum creatinine) every 2–3 days when combined. Monitor aminoglycoside trough levels to minimise aminoglycoside-driven nephrotoxicity. ℹ️ In practice, cephalexin (oral) and aminoglycosides (parenteral) are rarely co-prescribed — this combination is more relevant for parenteral cefazolin + gentamicin, but listed here for completeness.
Live vaccines (BCG, oral typhoid, oral polio, rotavirus)	Cephalexin (as an antibiotic) may theoretically reduce efficacy of oral live bacterial vaccines (oral typhoid — Ty21a; BCG) by killing the live vaccine organisms in the GI tract.	⚠️ Potential reduced vaccine efficacy for oral live bacterial vaccines.	Gradual onset.	Avoid concurrent administration of oral live bacterial vaccines during cephalexin therapy. Space vaccination by ≥3 days after completing the antibiotic course. No concern with injectable vaccines (DPT, hepatitis B, IPV, injectable typhoid Vi — all inactivated/subunit).

Food-Drug Interactions (MAJOR):

None. ✔ Cephalexin has no clinically significant food-drug interactions. It can be taken with any food, milk, dairy, juices, or supplements without affecting absorption. This is a major practical advantage and a key differentiator from cloxacillin/flucloxacillin.

Herb-Drug Interactions (MAJOR):

None documented. No clinically significant herb-drug interactions have been identified for cephalexin with any herbal or traditional medicine (including ashwagandha, giloy/guduchi, turmeric/curcumin, St. John’s Wort, triphala, arjuna). This is consistent with cephalexin’s lack of CYP/transporter involvement.

MODERATE DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Probenecid	Probenecid inhibits renal tubular secretion of cephalexin via OAT transporter blockade → increased cephalexin serum levels (AUC increase ~30–50%) and prolonged half-life (~50–100% increase).	Increased cephalexin exposure. Generally well-tolerated at this modestly elevated exposure. Historically, probenecid has been used intentionally to “boost” cephalosporin levels (similar to probenecid-penicillin). An FDC of cephalexin + probenecid is available in India (limited use).	Gradual onset (over 1–2 days of co-prescribing).	No mandatory dose adjustment at standard cephalexin doses when probenecid is co-prescribed for gout. Monitor for GI side effects (nausea, diarrhoea — may be slightly increased due to higher drug levels). If probenecid is used intentionally to boost cephalexin levels → no cephalexin dose change; the interaction is the desired effect.
Warfarin	Minimal interaction. Cephalexin is NOT a CYP inhibitor or inducer → does NOT directly affect warfarin metabolism. Theoretical interaction: broad-spectrum antibiotics may alter gut flora → reduced vitamin K synthesis → increased INR. For cephalexin (narrow-spectrum), this effect is very modest and rarely clinically significant.	Theoretical, minor increase in INR. Clinically significant bleeding due to cephalexin-warfarin interaction is extremely rare — only isolated case reports.	Gradual (if any — over 5–10 days of combined therapy).	No mandatory INR monitoring change for short courses (5–7 days). For prolonged cephalexin courses (>10 days) in patients on warfarin: check INR at 1 week as a precaution. Adjust warfarin only if INR is out of range. In routine practice, this interaction is clinically insignificant and should NOT prevent co-prescribing.
Oral contraceptive pills (OCPs)	No established interaction. Evidence does NOT support a clinically significant reduction in OCP efficacy with cephalexin or any cephalosporin. The theoretical concern (gut flora alteration → reduced enterohepatic recirculation of ethinyl estradiol) has been pharmacokinetically debunked for cephalosporins.	No clinical effect on OCP efficacy.	Not applicable.	No additional contraception needed. However, for medicolegal prudence in India, some practitioners counsel additional barrier contraception during antibiotic courses. This is a conservative, precautionary practice not supported by evidence for cephalexin.
Zinc supplements	Theoretical interaction: cephalexin is a substrate of the PEPT1 transporter for intestinal absorption. High-dose zinc supplements may theoretically compete at PEPT1 or alter intestinal absorption. Clinical significance is very uncertain and likely negligible.	Theoretical; likely no clinical effect.	Not applicable.	No action needed. Listed for completeness.
Cholestyramine / Colestipol (bile acid sequestrants)	Bile acid sequestrants may adsorb cephalexin in the GI tract if co-administered → reduced cephalexin absorption.	Potential reduced cephalexin levels if taken simultaneously.	Immediate (if taken together).	Stagger administration: Take cephalexin 1 hour before OR 4–6 hours after cholestyramine/colestipol. This is standard advice for most drugs interacting with bile acid sequestrants.
Mycophenolate mofetil (MMF)	Antibiotics may alter gut flora → reduced enterohepatic recirculation of mycophenolic acid (MPA) → reduced MPA exposure → potential transplant rejection risk. This interaction is more established for amoxicillin-clavulanate and fluoroquinolones than for cephalexin, but theoretically possible.	⚠️ Potentially reduced immunosuppressive efficacy of MMF.	Gradual (over days).	Monitor MPA trough levels if available. Watch for rejection signs. Minimise antibiotic course duration. Consult transplant team.
Diabetes medications (insulin, sulfonylureas, metformin)	No pharmacokinetic interaction. However, infection itself alters glycaemic control (hyperglycaemia during acute infection is common). Cephalexin does NOT directly affect blood glucose.	No direct drug-drug effect. Indirect: infection may worsen glycaemic control.	Not applicable.	Monitor blood glucose more frequently during acute infection (standard practice). No cephalexin dose adjustment for diabetes.

Herb-Drug Interactions (Moderate):

Herb / Traditional Medicine	Mechanism	Clinical Effect	Onset Type	Action Required
Giloy / Guduchi (Tinospora cordifolia)	No documented pharmacokinetic interaction with cephalexin. However, giloy has immunomodulatory properties and recent reports of giloy-associated DILI raise a general awareness concern. Cephalexin itself has negligible hepatotoxicity.	No significant interaction expected.	Not applicable.	No specific action. Patients self-medicating with giloy during an infection should inform their physician. No cephalexin dose adjustment.
Turmeric / Curcumin (dietary)	No interaction with cephalexin.	None.	Not applicable.	No restriction on dietary turmeric or curcumin supplements.
Grapefruit juice	✔ No interaction. Cephalexin is not a CYP3A4 substrate.	None.	Not applicable.	No restriction.
Dairy / Milk / Calcium	✔ No interaction. Unlike tetracyclines and fluoroquinolones, cephalexin does NOT chelate with calcium.	None.	Not applicable.	✔ Cephalexin can be taken freely with milk, dairy, and calcium supplements.
Iron supplements	✔ No significant interaction. Cephalexin does not chelate with iron.	None.	Not applicable.	✔ Can be co-administered with iron supplements without timing separation.

COMMON ADVERSE EFFECTS

ℹ️ Cephalexin is one of the best-tolerated oral antibiotics in clinical use. Its adverse effect profile is mild, predominantly gastrointestinal, and rarely requires discontinuation. Incidence data below are derived from clinical trial data, post-marketing surveillance, and regulatory databases.

Very Common (≥10%):

Adverse Effect	System	Incidence	Notes
Diarrhoea	GI	~10–15%	The most frequent adverse effect. Due to alteration of normal gut flora by the antibiotic. Usually mild, non-bloody, watery stools — self-limiting upon completion of therapy. Dose-response threshold: More common at higher doses (≥500 mg q6h / 2–4 g/day) and with courses >7 days. Taking cephalexin with food may reduce the incidence. ⚠️ If diarrhoea becomes severe (>6 stools/day), bloody, or accompanied by fever/abdominal cramps → evaluate for Clostridioides difficile infection (CDI).

Common (1–10%):

Adverse Effect	System	Incidence	Notes
Nausea	GI	~5–8%	Dose-dependent. More common at higher doses and on an empty stomach. ✔ Taking cephalexin with food significantly reduces nausea — this is one of the practical advantages of cephalexin (food-independent absorption allows taking with meals to reduce GI upset without compromising efficacy). Usually transient — improves over 1–2 days.
Abdominal pain / cramping	GI	~3–5%	Mild, non-specific. Usually transient. Does not typically require treatment or discontinuation.
Vomiting	GI	~2–4%	More common in children (especially with the oral suspension — less so than with cloxacillin but still occurs). If a child vomits within 30 minutes of a dose, the dose should be repeated. If vomiting occurs >30 minutes after dosing, do NOT repeat (sufficient absorption has likely occurred).
Dyspepsia / Epigastric discomfort	GI	~2–3%	Non-specific GI irritation. NOT true peptic ulcer disease. Taking with food helps. Does NOT routinely require PPI co-prescription.
Vaginal candidiasis	Infection (superinfection)	~3–5% (in women)	Due to suppression of vaginal bacterial flora → Candida overgrowth. More common with courses >7 days. Treat with topical clotrimazole pessary/cream or single-dose oral fluconazole 150 mg.
Oral candidiasis (thrush)	Infection (superinfection)	~1–3%	More common in young children, elderly, immunocompromised, and patients on concurrent inhaled corticosteroids. Treat with topical nystatin oral drops/gel or oral fluconazole.
Skin rash (non-urticarial, maculopapular)	Dermatological	~1–3%	Usually mild, appearing 3–10 days after starting therapy. Typically a non-IgE-mediated drug eruption (type IV hypersensitivity — delayed). Usually self-limiting upon completion. ⚠️ Must be distinguished from: (a) Urticarial rash (type I — IgE-mediated → risk of anaphylaxis progression), (b) SJS/TEN (mucosal involvement, skin pain, bullae), © DRESS (facial oedema, lymphadenopathy, eosinophilia, organ involvement).
Headache	CNS	~1–3%	Non-specific; mild. Not dose-dependent. Self-limiting.
Flatulence / Bloating	GI	~1–2%	Related to gut flora alteration. Mild and self-limiting.
Genital pruritus	GU	~1–2%	May indicate early vulvovaginal candidiasis. Examine for candidal signs.
Fatigue / Malaise	General	~1–2%	Mild. May be related to the underlying infection rather than the drug.

ℹ️ Overall tolerability note: Cephalexin’s GI adverse effect rate is lower than amoxicillin-clavulanate (where clavulanate drives significant GI upset, especially diarrhoea — reported at ~15–25%). This is a practical consideration when choosing between cephalexin and amoxicillin-clavulanate for indications where both are appropriate.

SERIOUS ADVERSE EFFECTS

⚠️ Serious adverse effects with cephalexin are rare. Cephalexin has one of the best safety profiles of any systemic antibiotic. The serious effects listed below, while important to know, occur at frequencies far below those seen with fluoroquinolones, clindamycin, anti-staphylococcal penicillins (hepatotoxicity), or sulfonamides.

Serious Adverse Effect	Approximate Frequency	System	Clinical Details	Action Required
Anaphylaxis / Anaphylactoid reaction	~0.01–0.05% (1 in 2,000 to 1 in 10,000 courses) — similar to other cephalosporins and penicillins	Immunological	Immediate (type I) hypersensitivity. Onset within minutes to 1 hour of dose (most commonly within first 30 minutes of the first dose — but can occur on any dose, including re-exposure after a period of sensitisation). Features: urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse. Can be fatal. Risk factors: prior penicillin/cephalosporin allergy (especially anaphylaxis history).	⛔ STOP cephalexin immediately. Administer Adrenaline (Epinephrine) 0.5 mg IM (1:1000 / 1 mg/mL — 0.5 mL into anterolateral thigh). Paediatric dose: 0.01 mg/kg IM (max 0.3 mg for children, 0.5 mg for adolescents/adults). Repeat every 5–15 min as needed. Supportive: IV fluids, oxygen, IV chlorpheniramine 10 mg (adult), IV hydrocortisone 200 mg (adult). Antidote: Adrenaline (epinephrine) — available at all levels of healthcare in India (NLEM drug). ⛔ Do NOT re-challenge with cephalexin or any cephalosporin. Document in medical record as permanent drug allergy. ⚠️ Report to PvPI.
Clostridioides difficile Infection (CDI) / Antibiotic-Associated Colitis	Uncommon (~0.5–2% of hospitalised patients; lower in outpatient setting)	GI / Infectious	Profuse watery diarrhoea (>6 stools/day), fever, abdominal cramps, leucocytosis, elevated CRP/ESR. Can progress to pseudomembranous colitis, toxic megacolon, colonic perforation, septic shock. Risk factors: elderly (>65 years), hospitalisation, concurrent PPI use, prior antibiotic exposure, immunosuppression, prior CDI. ℹ️ Cephalexin’s CDI risk is LOWER than fluoroquinolones, clindamycin, amoxicillin-clavulanate, or broad-spectrum cephalosporins — but still present (all antibiotics carry some CDI risk).	⛔ STOP cephalexin if CDI is suspected. Send stool for CDI testing (GDH + toxin EIA, or PCR). Start oral vancomycin 125 mg q6h × 10 days (first-line). Alternative: fidaxomicin 200 mg BD × 10 days. IV metronidazole 500 mg q8h as adjunct for severe/fulminant cases. ⛔ No anti-motility agents (loperamide). ⚠️ Report to PvPI.
Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	Very rare (<0.01% — <1 in 10,000 courses)	Dermatological / Systemic	Onset usually 7–21 days after starting therapy (shorter if prior sensitisation). Widespread erythematous macules → target lesions → bullae → skin detachment. Mucous membrane involvement (oral, genital, ocular). Systemic illness. Mortality: SJS 5–10%; TEN 25–35%.	⛔ STOP cephalexin immediately at first sign of widespread rash with mucosal involvement, skin pain/tenderness, or bullae. Do NOT wait for confirmation. Transfer to burn centre/ICU. Dermatology consultation. Supportive care (wound care, IV fluids, pain management). ⛔ NEVER re-challenge with any beta-lactam. ⚠️ Report to PvPI.
DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)	Very rare (<0.01%)	Immunological / Multi-system	Onset typically 2–8 weeks after starting therapy (later than most drug rashes). Features: widespread rash, facial oedema, fever, lymphadenopathy, eosinophilia (>1,500/mm³), atypical lymphocytosis, organ involvement (hepatitis most common; also nephritis, pneumonitis, carditis). Associated with HHV-6 reactivation. Mortality ~5–10%.	⛔ STOP cephalexin immediately. CBC with differential (eosinophils), LFT, renal function. Systemic corticosteroids under specialist supervision (prednisolone 1–2 mg/kg/day). Prolonged taper (weeks to months). ⛔ NEVER re-challenge. ⚠️ Report to PvPI.
Acute Interstitial Nephritis (AIN)	Rare (<0.1%)	Renal	Immune-mediated tubulointerstitial inflammation. Classic triad (often incomplete): fever, rash, eosinophilia + rising creatinine. Eosinophiluria, sterile pyuria. Onset typically 7–21 days after starting therapy. ℹ️ AIN is more commonly associated with methicillin/nafcillin and some second/third-generation cephalosporins than with cephalexin — but has been reported with cephalexin.	⛔ STOP cephalexin. Check renal function, urine analysis (eosinophils), CBC (eosinophil count). Most cases resolve with drug withdrawal. Corticosteroids (prednisolone 1 mg/kg/day × 2–4 weeks) may be considered by nephrologist if creatinine does not improve within 1 week. ⚠️ Report to PvPI.
Haemolytic Anaemia (Coombs-positive)	Very rare (<0.01%)	Haematological	Immune-mediated haemolytic anaemia — drug-dependent antibodies against RBC surface antigens. Can be associated with a positive direct antiglobulin test (DAT / direct Coombs test). ℹ️ A positive DAT can occur WITHOUT clinical haemolysis (false-positive DAT — see Cautions, Part 4). True haemolytic anaemia is extremely rare. If it occurs: jaundice, dark urine, pallor, fatigue, elevated LDH, elevated indirect bilirubin, low haptoglobin, reticulocytosis.	⛔ STOP cephalexin if haemolytic anaemia is confirmed. Supportive care (transfusion if severe, folate supplementation). Corticosteroids may be considered for severe cases. Haemolysis usually resolves within days to weeks of stopping the drug. ⛔ Do NOT re-challenge with cephalexin. ⚠️ Report to PvPI.
Seizures / Neurotoxicity	Extremely rare at standard therapeutic doses with normal renal function. Risk increases with drug accumulation in severe renal impairment with unadjusted dosing.	CNS	All beta-lactams have proconvulsant potential via GABA-A receptor antagonism at very high CNS concentrations. For cephalexin, this risk is virtually negligible at standard therapeutic doses (250–500 mg q6–8h) with normal renal function. Risk factors: CrCl <10 mL/min with unadjusted dosing, pre-existing seizure disorder, concurrent intrathecal chemotherapy.	If seizures occur: consider drug accumulation → check renal function → reduce dose or extend interval. Treat seizures with benzodiazepines (lorazepam 2–4 mg IV or diazepam 5–10 mg IV). Cephalexin-related seizures are extremely uncommon — always rule out other causes first (metabolic, infectious, structural).
Serum Sickness-Like Reaction	Rare (<0.1%)	Immunological	Type III hypersensitivity (immune complex-mediated). Onset 7–21 days. Fever, arthralgia, urticarial or purpuric rash, lymphadenopathy. Self-limiting after drug withdrawal. ℹ️ More commonly reported in children than adults, and more commonly associated with cefaclor than cephalexin — but has been reported with cephalexin.	⛔ STOP cephalexin. NSAIDs for arthralgia/fever. Antihistamines for urticaria. Short corticosteroid course if severe. Resolves within 1–3 weeks of stopping.

Specific antidote information:

Toxicity	Antidote	Dose	Availability in India
Anaphylaxis	Adrenaline (Epinephrine)	0.5 mg IM (adult); 0.01 mg/kg IM (child, max 0.3 mg) — repeat every 5–15 min as needed	✔ Available at all healthcare levels in India. On NLEM. Every clinic/hospital should stock adrenaline.
Cephalexin overdose	No specific antidote.	Supportive care. GI decontamination (activated charcoal if within 1 hour of massive ingestion). Haemodialysis removes ~30–40% of drug.	Supportive care available universally. HD available at district hospitals and above.

ℹ️ Cephalexin overdose is very rarely clinically significant due to the drug’s wide therapeutic index. Even at doses several times the recommended maximum, toxicity is usually limited to severe GI symptoms (nausea, vomiting, diarrhoea). Neurotoxicity (seizures) is possible only at extreme overdoses with concurrent renal failure.

CDSCO safety alerts / Black-box equivalent warnings:

No specific CDSCO black-box warning or REMS-type requirement exists for cephalexin as of 2024. No specific Indian regulatory safety alert has been issued for cephalexin. The drug has an established safety record spanning over 50 years of clinical use.

⚠️ PvPI reporting reminder: For ALL serious adverse effects listed above: Report to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website (https://www.cdsco.gov.in). PvPI toll-free helpline: 1800-180-3024. ADR reporting also available via the Med Safety app (WHO/PvPI).

Early warning signs the prescriber should educate ALL patients receiving cephalexin about:

💡 Instruct all patients to report immediately if they develop:

Skin rash of any kind — especially if spreading, blistering, or involving mouth/eyes/genitals
Swelling of face, lips, tongue, or throat; difficulty breathing (anaphylaxis warning)
Severe or bloody diarrhoea (CDI warning)
Unusual tiredness, pale skin, dark urine, yellowing of eyes (haemolytic anaemia — very rare)
Significant reduction in urine output (renal — very rare)

MONITORING REQUIREMENTS

ℹ️ Cephalexin requires minimal monitoring for standard short courses (5–10 days) in patients with normal renal function. This is one of its practical advantages for outpatient and primary care prescribing. Monitoring becomes more relevant for prolonged courses (>2 weeks), high-dose therapy (osteomyelitis), and patients with renal impairment.

Baseline (Before Starting Therapy)

Parameter	Grading	Details
Allergy history	MANDATORY	Ask specifically about prior reactions to ANY cephalosporin, penicillin, or other beta-lactam. Characterise the reaction (timing, features) to distinguish true allergy from non-allergic ADR. See allergy cross-reactivity guidance (Part 4).
Culture and sensitivity	RECOMMENDED (for UTI, complicated SSTI, treatment failure, recurrent infections). OPTIONAL for first-episode uncomplicated SSTI where empiric cephalexin is reasonable.	Obtain appropriate specimens (urine culture, wound swab) BEFORE starting antibiotics when feasible. Empiric therapy can be started while awaiting results.
Serum creatinine / eGFR	RECOMMENDED — in elderly (≥60 years), diabetics, patients with known CKD, and those planned for prolonged or high-dose courses. OPTIONAL for young, healthy patients on short courses.	Cephalexin is ~80–95% renally excreted. Dose adjustment needed at CrCl <30 mL/min.
CBC	OPTIONAL — for routine short courses. RECOMMENDED if prolonged course (>2 weeks) or high-dose therapy is planned.	Baseline for comparison if haematological ADR suspected later.
Pregnancy test	OPTIONAL — in women of reproductive age if pregnancy is uncertain and the clinical scenario requires knowing pregnancy status (e.g., UTI management — choice of antibiotic may differ).	Cephalexin is safe in pregnancy — but knowing pregnancy status informs overall management.

Resource-limited setting surrogates:

If renal function cannot be tested: Enquire about known kidney disease, diabetes, use of nephrotoxic drugs. Assess urine output. Use standard dosing with clinical vigilance in healthy young patients. Refer for renal function testing if prolonged course is planned.
If cultures unavailable (common in PHC/CHC): Empiric therapy is acceptable for first-episode uncomplicated infections. Refer for culture if treatment failure or recurrence.

After Initiation / Dose Change

Parameter	Grading	When to Check	Details
Clinical response	MANDATORY	At 48–72 hours (all infections)	Expect symptom improvement within 48–72 hours. If no improvement → reassess (resistant organism? Wrong diagnosis? Deeper infection? Non-adherence?).
Renal function	RECOMMENDED (for prolonged/high-dose courses, elderly, diabetics)	At 1 week for standard courses; every 1–2 weeks for prolonged courses	Watch for rising creatinine (AIN — rare).
Follow-up urine culture	RECOMMENDED (for UTI — especially pyelonephritis, pregnancy, paediatric UTI, treatment failure)	At end of therapy or 1–2 weeks after completing therapy	Test of cure — confirm bacteriological eradication. Especially important in pregnancy (untreated/persisting bacteriuria → pyelonephritis risk).

Long-Term / Maintenance Monitoring (For Prolonged Courses >2 Weeks)

Parameter	Grading	Frequency	Details
CBC	RECOMMENDED	Every 2 weeks	Watch for neutropenia (very rare with cephalexin — but reported with prolonged courses of any beta-lactam), thrombocytopenia (very rare), eosinophilia (may indicate hypersensitivity reaction developing).
Renal function	RECOMMENDED	Every 2 weeks	Monitor for AIN or drug accumulation in patients with borderline renal function.
CRP/ESR	RECOMMENDED (for osteomyelitis / serious infections)	Weekly during the oral phase	Guide treatment response and duration decisions. CRP should decline progressively.
Clinical assessment for superinfection	RECOMMENDED	At every follow-up visit	Check for oral thrush, vaginal candidiasis, CDI symptoms.

Therapeutic Drug Monitoring (TDM)

TDM is NOT required and NOT available for cephalexin in Indian clinical practice. Cephalexin has a wide therapeutic index — therapeutic and toxic dose ranges are well-separated, making TDM unnecessary. Dosing is based on indication, body weight (paediatrics), and renal function.

ℹ️ In the rare research/ICU context where TDM might be considered (e.g., verifying drug levels during high-dose oral therapy for osteomyelitis): target free cephalexin trough >MIC of the pathogen (typically >4–8 mg/L for MSSA). TDM for cephalexin is NOT available at any routine clinical laboratory in India (or internationally) — it is exclusively a research tool.

When to stop monitoring:

Short courses (≤10 days) in healthy patients: No ongoing monitoring needed after completion.
Prolonged courses: Stop monitoring (CBC, renal) at course completion if values were stable throughout.
UTI follow-up cultures: Single post-treatment culture at 1–2 weeks is usually sufficient.

PATIENT COUNSELLING

Written in simple language that a doctor can directly convey to the patient during consultation.

What this medicine is for:
“This medicine fights germs (bacteria) that cause infections in your skin, urine (bladder/kidneys), throat, ears, and bones. It kills the germs and helps your body heal.”

How to take it:

“You can take this medicine with food or on an empty stomach — either is fine. Taking it with food may help if you feel sick (nauseous) after taking it.”
“Swallow the capsule whole with a full glass of water (at least one cup).”
“If you are taking the liquid (syrup) form, shake the bottle well before each dose. Use the measuring cup or syringe provided — do NOT use a household teaspoon.”
“Try to take your doses at evenly spaced times through the day. For example, if you take it 3 times a day — take it morning, afternoon, and bedtime.”
“You can take this medicine with milk, tea, juice, or food — there is no restriction.”

What to do if you miss a dose:
“If you forget a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next one at the regular time. Never take two doses at the same time.”

Common side effects to expect:
“You may experience some of these — they are usually mild and get better on their own:”

“Loose motions (diarrhoea) — this is the most common side effect. The medicine kills some good bacteria in your stomach along with the bad ones. Drink plenty of water and ORS. If the loose motions are very bad, watery, or have blood — come to the hospital.”
“Mild nausea or stomach discomfort — taking the medicine with food usually helps.”
“White patches in the mouth (thrush) or itching in the private area — this is a yeast infection caused by the medicine killing good bacteria. It can be easily treated — tell your doctor.”

⚠️ Warning signs — come to the hospital IMMEDIATELY if you develop:

“Skin rash — especially if it is spreading, has blisters, or involves your mouth, eyes, or private parts”
“Swelling of your face, lips, tongue, or throat / difficulty breathing — this could be a serious allergic reaction”
“Severe diarrhoea — more than 6 watery stools a day, or diarrhoea with blood or severe stomach cramps”
“Very little urine or no urine at all”
“Yellow colour in your eyes or skin (very rare with this medicine, but report it)”
“Unusual tiredness, pale skin, or dark urine”

Things to avoid:

“There are no specific foods to avoid with this medicine. You can eat and drink normally.”
“You can take this medicine with milk and dairy products — no problem (unlike some other antibiotics).”
“Avoid drinking excessive alcohol — it may worsen stomach problems and is not helpful while fighting an infection.”

Storage:

“Keep capsules/tablets in a cool, dry place below 30°C. Do NOT store in the bathroom.”
“If using the liquid (syrup): keep it in the fridge after mixing. Use within 14 days (or 7 days if no fridge is available). Write the date of preparation on the bottle.”
“In hot weather, keep medicine away from direct sunlight and heat.”
“Keep all medicines out of reach of children.”

Duration:

“Take the full course of medicine as prescribed by your doctor, even if you feel better after 2–3 days.”
“Stopping early can cause the infection to come back, and the germs may become harder to treat next time.”
“This is especially important for throat infections — you must take the medicine for a full 10 days to protect your heart from a complication called rheumatic fever.”
“Do NOT save leftover capsules or syrup for future use — antibiotics should only be taken when prescribed by a doctor.”

Follow-up:

“Come back for review as advised by your doctor — usually after 3–5 days for skin infections, or sooner if your symptoms are not improving.”
“If your doctor has asked for a urine test after finishing the medicine, please get it done — this checks whether the infection is fully cleared.”

Common patient questions addressed:

Question	Answer
“Can I take this with my other medicines?”	“This medicine usually does not interfere with other medicines. But tell your doctor about ALL medicines you are taking, especially blood thinners (warfarin) or medicines for joint pain (methotrexate). Also tell about any Ayurvedic, homeopathic, or herbal medicines.”
“Can I take this with milk?”	“Yes! Unlike some other antibiotics, this medicine can be taken with milk, curd, buttermilk, or any dairy product without any problem.”
“Can I take this during fasting (Ramadan / Navratri / Ekadashi)?”	“This medicine needs to be taken 2–3 times a day. If you are fasting and eating only once or twice a day, discuss with your doctor. You may be able to adjust the timing — for example, take one dose at suhoor (pre-dawn meal) and one at iftar (evening meal) for a twice-daily schedule. Do NOT skip doses during fasting without asking your doctor.”
“Will this affect my ability to drive or work?”	“No — this medicine does NOT cause drowsiness or affect your ability to drive, operate machines, or do your daily work.”
“Is this medicine habit-forming?”	“No — antibiotics are not habit-forming. But they should only be taken when prescribed by a doctor for a specific infection.”
“Can I stop once I feel better?”	“No — please complete the full course. Stopping early can cause the infection to come back stronger. This is especially important for throat infections (10-day course).”
“I have a penicillin allergy — can I take this?”	“Tell your doctor about your allergy. This medicine is related to penicillin but is usually safe for people with mild penicillin allergy (e.g., only a mild rash). However, if you have had a SEVERE allergic reaction to penicillin (swelling, breathing difficulty, hospitalisation), your doctor will decide whether this medicine is safe for you or will prescribe a different one.”
“Can I give this to my child?”	“Yes — this medicine is commonly and safely used in children. Your doctor will calculate the correct dose based on your child’s weight. Use the measuring device provided — not a household spoon. Give the liquid form (syrup) if your child cannot swallow capsules.”

Caregiver / Family Counselling (Paediatric / Elderly / Dependent Patients):

“Counsel the caregiver/family member on:”

Correct dose measurement: “Always shake the bottle well. Use the measuring cup or oral syringe provided — do NOT use a household spoon (doses will be inaccurate).”
Giving medicine to a reluctant child: “The syrup has a fruity taste but some children may still resist. You can mix the measured dose with a small amount of juice, milk, or soft food (jam, yogurt) and give it immediately. Unlike some other antibiotics, this medicine can be mixed with food without any problem.”
Completing the full course: “Even if your child seems completely well after 2–3 days, give ALL the medicine as prescribed. For throat infections — the full 10 days is essential to protect the heart.”
Vomiting after dose: “If your child vomits within 30 minutes of taking the medicine, give the dose again. If vomiting happens after 30 minutes, do NOT give extra.”
Storing the liquid: “Keep in the fridge after mixing. If no fridge: keep in the coolest part of the house and use within 5–7 days.”
Warning signs: “Bring the child/patient to the hospital immediately if you notice: skin rash, blisters, swelling of face or lips, blood in stool, the child is not feeding, or seems more sick instead of getting better.”

India-specific adherence support:

Barrier	Guidance
Cost-driven non-adherence	“This medicine is available as an affordable generic. If cost is a concern, ask your doctor about generic (unbranded) cephalexin — it is much cheaper than branded versions. You can also check at Jan Aushadhi / PMBJP stores near you for the lowest-cost option.”
Polypharmacy burden	“If you are taking many medicines, bring all your medicines to each doctor visit. Ask your doctor to review which ones are essential.”
Rural access / refill difficulty	“If you cannot get a refill on time, contact your doctor by phone. Do NOT stop the antibiotic course without asking. Try to get the full course dispensed at once so you have all the medicine you need.”
Temperature-sensitive storage	“The liquid (syrup) form needs to be kept cold after mixing. If you live in a hot area and do not have a fridge, ask your doctor if capsules can be used instead (if the child can swallow them). Capsules do not need cold storage.”
Stigma	Not applicable for cephalexin (no stigma associated with antibiotic use).

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP brands:

ℹ️ Cephalexin capsules and dry syrup are available through Jan Aushadhi (PMBJP) stores under the generic name “Cephalexin Capsules” and “Cephalexin Dry Syrup.”

Jan Aushadhi Cephalexin Capsules 250 mg — available at PMBJP stores
Jan Aushadhi Cephalexin Capsules 500 mg — available at PMBJP stores
Jan Aushadhi Cephalexin Dry Syrup 125 mg/5 mL — available at select PMBJP stores (verify availability at your nearest store)

ℹ️ Availability varies by state and store. Larger PMBJP stores near government hospitals are more likely to stock cephalexin. Store locator: https://janaushadhi.gov.in

Major Private Brands (Commonly Available):

Brand Name	Manufacturer	Formulations Available	Availability
Sporidex	Sun Pharmaceutical Industries	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL; Drops; Tablets	Widely available — one of the most recognised cephalexin brands in India
Phexin	GSK Pharmaceuticals (now various — legacy brand)	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL; Drops; Redimix (ready-to-use suspension)	Widely available
Ceff	Lupin Limited	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL	Widely available
Alcephin	Alkem Laboratories	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL	Widely available
Keflex (originator brand name — limited availability in India now; generic usage is dominant)	Various / originator: Eli Lilly (historical)	Capsules	Limited availability — primarily referenced as the originator name internationally
Lexin	Various manufacturers	Capsules 250 mg, 500 mg	Regional availability
Cephadex	Various	Capsules 250 mg, 500 mg; Dry syrup	Regional availability
Ospexin	Sandoz / Novartis (legacy)	Capsules 250 mg, 500 mg	Major metros; limited in smaller cities

Paediatric drops brands:

Brand Name	Manufacturer	Formulation	Availability
Sporidex Drops	Sun Pharma	Drops 125 mg/1.25 mL	Major pharmacies — not universally stocked
Phexin Drops	GSK (legacy)	Drops 125 mg/1.25 mL	Major pharmacies

Dispersible tablet brands:

Limited manufacturers produce cephalexin dispersible tablets in India. These are available from select regional manufacturers — verify local availability if specifically needed for patients who cannot swallow capsules and for whom suspension is unavailable.

CDSCO NSQ (Not of Standard Quality) Alerts:

ℹ️ Cephalexin formulations from various manufacturers have intermittently appeared on CDSCO NSQ alert lists. Common findings include subpotent assay (drug content below labelled claim) and dissolution failures. These are generally batch-specific issues.

Recommendation: Procure from established manufacturers with robust quality systems. Check CDSCO NSQ alerts periodically (https://cdsco.gov.in → Drug Safety → NSQ Alerts). Report any suspected quality issue to the State Drug Controller.

PRICE RANGE (INR)

Prices as of May 2025. Verify current prices on NPPA website / 1mg / PharmEasy / Jan Aushadhi price lists as prices may change.

Single-ingredient Cephalexin:

Formulation	Strength	Price Range (Per Unit — Private Market)	NPPA Controlled?	Jan Aushadhi Price (Estimated)	Notes
Capsule	250 mg	₹3–8 per capsule	✔ NPPA price-controlled (on NLEM India 2022)	₹1.50–3 per capsule	Government supply significantly cheaper
Capsule	500 mg	₹5–12 per capsule	✔ NPPA controlled	₹3–5 per capsule	Most commonly prescribed strength
Tablet	250 mg	₹3–7 per tablet	✔ NPPA controlled	₹2–4 per tablet
Tablet	500 mg	₹5–12 per tablet	✔ NPPA controlled	₹3–5 per tablet
Dry syrup	125 mg/5 mL (30 mL bottle)	₹20–50 per bottle	✔ NPPA controlled	₹15–25 per bottle
Dry syrup	250 mg/5 mL (30 mL bottle)	₹30–70 per bottle	✔ NPPA controlled	₹20–35 per bottle
Drops	125 mg/1.25 mL (10 mL bottle)	₹40–80 per bottle	✔ NPPA controlled	Data limited	Limited availability

Per-Course Cost Estimates:

Clinical Scenario	Dose	Duration	Number of Capsules (500 mg)	Estimated Cost (Generic/NPPA)	Estimated Cost (Branded)
Uncomplicated SSTI — 500 mg TDS × 7 days	500 mg q8h	7 days	21 capsules	₹63–105	₹105–250
GAS pharyngitis — 500 mg BD × 10 days	500 mg q12h	10 days	20 capsules	₹60–100	₹100–240
Uncomplicated UTI — 500 mg q8h × 5 days	500 mg q8h	5 days	15 capsules	₹45–75	₹75–180
Osteomyelitis oral step-down — 1 g q6h × 4 weeks	1 g q6h (2 × 500 mg per dose)	4 weeks	224 capsules	₹670–1,120	₹1,120–2,700
UTI prophylaxis — 250 mg OD at bedtime × 6 months	250 mg OD	~180 days	180 capsules (250 mg)	₹270–540	₹540–1,440

ℹ️ Cost comparison: Cephalexin is one of the most affordable oral antibiotics in India. It is substantially cheaper than amoxicillin-clavulanate, cefuroxime axetil, cefixime, and fluoroquinolones for equivalent courses. This cost advantage, combined with NLEM listing and NPPA price control, makes cephalexin an excellent choice for cost-conscious prescribing.

ℹ️ Government supply: Government hospitals and CGHS/state supply chains procure cephalexin at prices substantially below NPPA ceiling (often 40–60% below retail).

ℹ️ PMBJP (Jan Aushadhi) availability: ✔ Available. Direct patients to their nearest PMBJP store for the most affordable option.

CLINICAL PEARLS

💡 Pearl 1: Food-independence is cephalexin’s greatest practical advantage — leverage it. [Evidence-based]
Cephalexin’s ~90–95% oral bioavailability is unaffected by food — unlike cloxacillin (~50% reduction with food) and flucloxacillin (~25–35% reduction). For outpatient oral MSSA/streptococcal infections, this translates to dramatically better adherence. A patient who takes cephalexin 500 mg TDS with meals will achieve adequate drug levels. A patient “supposed to” take cloxacillin 500 mg QDS on an empty stomach — but who actually takes it with meals because the instructions are impractical — will have subtherapeutic levels and risk treatment failure. The best antibiotic is the one the patient actually takes correctly.

💡 Pearl 2: Cephalexin can be taken with milk — a huge advantage in Indian practice. [Evidence-based]
Unlike tetracyclines and fluoroquinolones (which chelate with calcium), cephalexin has NO interaction with milk, dairy, or calcium. In India, where milk/chai/curd is a dietary staple and children’s diets are heavily milk-based, this is a significant practical advantage. Counsel patients and families affirmatively: “You can take this medicine with milk, curd, buttermilk, or any food — no restrictions.” This positive message improves adherence far more than a list of restrictions.

💡 Pearl 3: Myth vs Fact — “Cephalexin is weaker than cloxacillin for staph infections.” [Evidence-based]
Myth: Cloxacillin has a lower MIC against MSSA, so it must be a better drug.
Fact: While cloxacillin’s MIC against MSSA is lower (~0.5–1 mg/L vs ~4–8 mg/L for cephalexin), this comparison ignores protein binding. Cloxacillin is ~95% protein-bound (only ~5% free drug). Cephalexin is ~10–15% protein-bound (~85–90% free drug). The free drug concentration — which is what actually kills bacteria — is much closer between the two drugs than the total drug concentrations suggest. Multiple clinical studies show equivalent outcomes for mild-to-moderate MSSA SSTI with cephalexin vs cloxacillin. For serious/deep-seated MSSA infections (bacteraemia, endocarditis), anti-staphylococcal penicillins are still preferred — but for outpatient SSTI, the theoretical potency advantage of cloxacillin is offset by cephalexin’s vastly superior adherence profile.

💡 Pearl 4: BD cephalexin for GAS pharyngitis — a game-changer for ARF prevention adherence. [Evidence-based]
Cephalexin 500 mg twice daily (BD) for 10 days has been shown in RCTs (Pichichero et al.) to achieve GAS bacteriological eradication rates equivalent to penicillin V QDS for 10 days. In India, where RHD prevention depends on completing the full 10-day course of antibiotics for GAS pharyngitis, the simpler the regimen, the more likely it will be completed. Two doses per day is enormously more achievable than four — especially for school-going children and working adults. When prescribing for GAS pharyngitis, default to the BD regimen unless there is a specific reason to use TDS/QDS.

💡 Pearl 5: Cefazolin → Cephalexin IV-to-oral switch is pharmacologically ideal. [Practice-based]
When stepping down from IV cefazolin (the workhorse first-generation parenteral cephalosporin) to an oral agent, cephalexin is the natural choice — both are first-generation cephalosporins with nearly identical spectra. This switch is pharmacologically consistent, well-validated by clinical experience, and avoids the cross-class issues of switching from a cephalosporin to a penicillin (e.g., cefazolin → cloxacillin — different pharmacokinetic/pharmacodynamic profiles, different dosing requirements, different food effects). Document the switch rationale in the patient’s notes and ensure the oral dose is appropriate for the indication (500 mg q8h for SSTI; 1 g q6h for osteomyelitis).

💡 Pearl 6: Cephalexin is among the safest antibiotics for patients with liver disease, pregnancy, lactation, and the elderly. [Evidence-based]
No hepatic metabolism, no hepatotoxicity, no CYP interactions, no anticholinergic effects, no QT prolongation, safe in all trimesters of pregnancy, safe during breastfeeding, minimal drug interactions, wide therapeutic index. For a clinician choosing an antibiotic in a patient with multiple comorbidities (elderly diabetic on warfarin with CKD and liver disease — a common Indian patient profile), cephalexin is one of the safest choices available — provided the infection is within its spectrum (MSSA/streptococcal SSTI, uncomplicated UTI). Adjust dose for renal function, and you’re done.

VERSION

RxIndia v0.5 — 16 Mar 2026

REFERENCES

The following sources were actually used to generate this monograph:

CDSCO Product Inserts — Sporidex (cephalexin), Sun Pharmaceutical Industries; Phexin (cephalexin), GSK Pharmaceuticals India; Ceff (cephalexin), Lupin Limited. Revision dates not uniformly available; data extracted from the most recently accessible package inserts (accessed 2024).
Indian Pharmacopoeia (IP) 2022, Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Cephalexin (Cefalexin) — identity, assay, standards.
National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Cephalexin listed under Section 6.2 — Antibacterials (beta-lactam medicines, cephalosporins).
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Brunton LL, Hilal-Dandan R, Knollmann BC (Eds). Chapter 58: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. Used for pharmacology depth, PK parameters, spectrum of activity, mechanism of action, and drug interaction data.
Harrison’s Principles of Internal Medicine, 21st Edition (2022). Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (Eds). Chapters on: Skin and Soft Tissue Infections, Urinary Tract Infections, Pharyngitis, Osteomyelitis, Infective Endocarditis. Used for disease management context and clinical indications.
API Textbook of Medicine, 12th Edition (2022). Association of Physicians of India. Chapters on: Antimicrobial Therapy, Skin and Soft Tissue Infections, Urinary Tract Infections, Streptococcal Infections, Rheumatic Fever. Used for Indian clinical practice context.
IAP (Indian Academy of Pediatrics) Guidelines — Drug Formulary and Treatment Guidelines for paediatric infections; IAP Guidelines on GAS Pharyngitis and ARF prevention; IAP UTI Guidelines; IAP AOM Guidelines. Year: 2019–2023 guidelines.
NNF (National Neonatology Forum) India — Drug Doses handbook (latest edition). Referenced for neonatal dosing principles (limited specific data for cephalexin).
ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019, updated 2022). Indian Council of Medical Research. Used for India-specific empiric antibiotic recommendations, resistance patterns, and UTI management.
ICMR Antimicrobial Resistance Surveillance Network — Annual Reports (2022–2023). Used for Indian resistance data for E. coli, K. pneumoniae, and S. aureus against cephalexin.
AIIMS Antibiotic Policy — All India Institute of Medical Sciences, New Delhi. Referenced for institutional antibiotic recommendations and IV-to-oral switch protocols.
IDSA SSTI Guidelines — Stevens DL, Bisno AL, Chambers HF, et al. “Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America.” Clin Infect Dis. 2014;59(2):e10-e52. Used for SSTI classification, treatment recommendations, and duration guidance.
IDSA/ESCMID Uncomplicated UTI Guidelines — Gupta K, Hooton TM, Naber KG, et al. “International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the IDSA and ESCMID.” Clin Infect Dis. 2011;52(5):e103-e120. (2024 update also referenced for current recommendations.) Used for UTI treatment hierarchy and cephalexin’s role as a second-line agent.
DANCE Trial — Dan JM, et al. “Clinical Cure with 5 Days versus 10 Days of Antibiotics for Uncomplicated Cellulitis.” Clin Infect Dis. 2017. Referenced for short-course cellulitis evidence.
Pichichero ME, Casey JR. “Comparison of cephalosporin and penicillin treatment of group A streptococcal pharyngitis.” Multiple publications (Pichichero et al., 2000; Casey & Pichichero, 2004, 2007). Used for evidence supporting BD cephalexin for GAS pharyngitis and cephalosporin vs penicillin meta-analysis.
OVIVA Trial — Li HK, Rombach I, Zamber R, et al. “Oral versus Intravenous Antibiotics for Bone and Joint Infection.” N Engl J Med. 2019;380(5):425-436. DOI: 10.1056/NEJMoa1710926. Referenced for oral step-down evidence in bone/joint infections.
Peltola H, Pääkkönen M, et al. Paediatric osteomyelitis RCTs — “Short- versus Long-Term Antimicrobial Treatment for Acute Hematogenous Osteomyelitis of Childhood.” Pediatr Infect Dis J. 2010;29(12):1123-1128. And: “Prospective, Randomized Trial for Childhood Septic Arthritis.” Clin Infect Dis. 2009. Used for paediatric bone/joint infection duration and oral step-down evidence.
AHA IE Prophylaxis Guidelines — Wilson WR, Taubert KA, Gewitz M, et al. “Prevention of Infective Endocarditis: Guidelines from the AHA.” Circulation. 2007 (updated 2021). Used for IE prophylaxis indications and cephalexin dosing.
FOGSI (Federation of Obstetric & Gynaecological Societies of India) Guidelines — UTI in pregnancy management. Referenced for cephalexin use in pregnancy UTI.
WHO Mastitis Guidelines — Mastitis: Causes and Management. WHO/FCH/CAH/00.13. Referenced for mastitis treatment.
RIVUR Trial — “Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux.” N Engl J Med. 2014;370(25):2367-2376. Referenced for UTI prophylaxis in VUR.
NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) and NPPA ceiling prices for NLEM drugs. Accessed 2024–2025.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Jan Aushadhi product catalogue. Reviewed to confirm cephalexin availability and estimated pricing. Accessed 2024–2025.
PvPI (Pharmacovigilance Programme of India) — CDSCO. Referenced for ADR reporting mechanisms and pharmacovigilance requirements.

Cephalosporins

Sub-classifications

Cumulative Drug Index

Quick Links